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ADAPTATION AND SENSITIZATION TO PROTEOTOXIC STRESS
Rehana K. Leak  Division of Pharmaceutical Sciences, Mylan School of
Pharmacy, Duquesne University
 Although severe stress can elicit toxicity, mild stress often elicits adaptations. Here we
review the literature on stress-induced adaptations versus stress sensitization in models of
neurodegenerative diseases. We also describe our recent findings that chronic proteotox-
ic stress can elicit adaptations if the dose is low but that high-dose proteotoxic stress sen-
sitizes cells to subsequent challenges. In these experiments, long-term, low-dose protea-
some inhibition elicited protection in a superoxide dismutase-dependent manner. In con-
trast, acute, high-dose proteotoxic stress sensitized cells to subsequent proteotoxic chal-
lenges by eliciting catastrophic loss of glutathione. However, even in the latter model of
synergistic toxicity, several defensive proteins were upregulated by severe proteotoxicity.
This led us to wonder whether high-dose proteotoxic stress can elicit protection against
subsequent challenges in astrocytes, a cell type well known for their resilience. In support
of this new hypothesis, we found that the astrocytes that survived severe proteotoxicity
became harder to kill. The adaptive mechanism was glutathione dependent. If these find-
ings can be generalized to the human brain, similar endogenous adaptations may help
explain why neurodegenerative diseases are so delayed in appearance and so slow to
progress. In contrast, sensitization to severe stress may explain why defenses eventually col-
lapse in vulnerable neurons.
Key words: dual hit; two hit; Parkinson’s disease, Alzheimer’s disease, preconditioning, hormesis, 
U-shaped
INTRODUCTION
It has long been observed that organisms can adapt to mild stress but
are weakened by exposure to severe stress. Many decades ago, the father
of toxicology, Phillipus von Hohenheim (also known as Paracelsus),
observed that the dose makes the poison (Ottoboni 1997). Despite the
dearth of scientific data in the 1500s, Paracelsus suggested that anything
can be toxic in high doses and, conversely, that many poisons are not
toxic in low doses. Hans Selye, who described biological responses to
stress in the first half of the 20th century, also categorized stress into two
forms: eustress and distress (Selye 1975). Eustress was defined as mild
stressors that improve behavioral function and could be contrasted with
severe stressors that exert a negative impact on adaptive behavior. Selye’s
seminal studies demonstrated that the response to stress is largely dura-
tion-dependent. Stress initially elicits a phase of resistance in animals,
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whereas chronic stress that is unyielding results in distress. Both of these
pioneers, Paracelsus and Selye, therefore described two features that
strongly influence the direction of the response to stress: dose and dura-
tion. A plethora of more recent studies have largely confirmed their ini-
tial suspicions and also identified underlying mechanisms.
Our recent mechanistic studies on adaptations as well as sensitizations
to stress are the subject of the present review. It will become evident from
our studies that even long duration stress can elicit adaptations in some
cellular models provided the stressor dose is low, and that even high dose
stress can elicit adaptations in some cell types. However, in other cellular
models, severe stress elicits synergistic toxicity when combined with a sec-
ond challenge. Thus, the response to stress is not unidirectional and is
probably highly dependent on stressor dose, stressor duration, cell type,
brain region, prosurvival protein profile, organismal age, and many other
factors. Our models of stress all revolve around proteotoxicity, stress
caused by protein misfolding and aggregations. Proteotoxic stress is a
hallmark pathology of neurodegenerative diseases (Walker and LeVine
2000; Walker et al. 2006; Morimoto 2008; Dickson 2009; Jellinger 2009;
Uversky 2009; Angot et al. 2010; Gundersen 2010; Morimoto 2011). Many
neurodegenerative conditions, including the more common Alzheimer’s
and Parkinson’s diseases, are therefore known as proteinopathies. Each
of these diseases is characterized by signature protein aggregations or
inclusions in specific brain regions. Not surprisingly, there are also reduc-
tions in proteasome activity in both Parkinson’s and Alzheimer’s disease
(Keller et al. 2000; McNaught et al. 2003; McNaught 2004). The barrel-
shaped ubiquitin-proteasome system degrades misfolded proteins that
are tagged with a polyubiquitin tail. Although proteasome inhibition can-
not mimic the full extent of the pathologies in neurodegenerative dis-
eases, inhibition of proteasome activity with pharmacological tools elicits
some of the salient features of these disorders, such as the formation of
protein aggregations and cell death (Rideout et al. 2001; Rideout and
Stefanis 2002; Sawada et al. 2004; Rideout et al. 2005; Sun et al. 2006; Xie
et al. 2010). Another important caveat of current models of neurodegen-
eration is that they fail to mimic the decades-long pathophysiology of
chronic neurodegenerative diseases. This is a difficult obstacle to over-
come for the entire field and can be attributed to our lack of knowledge
of the primary cause of these disorders, the short rodent lifespan, and the
acute nature of insults applied to in vitro models of neurodegeneration.
On the other hand, studies on genetic or familial forms of Alzheimer’s
and Parkinson’s disease strongly support the hypothesis that abnormally
shaped proteins are causally linked to neurodegeneration. Despite this
significant advance, our lack of knowledge of the original stimulus that
first precipitates protein misfolding in sporadic forms of Alzheimer’s and
Parkinson’s disease has stalled the identification of curative therapies and
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hindered the development of animal and cellular models. Until we iden-
tify the reason for protein aggregation in sporadic forms of these diseases,
eliciting proteotoxicity with proteasome inhibition in cellular models or
by direct infusion into the brain appears to be a reasonable and practical
model of protein misfolding stress (Fornai et al. 2006; Pan et al. 2008;
Vernon et al. 2010; Zhang et al. 2012). Another form of proteotoxicity in
neurodegenerative disorders is the presence of autophagic stress (Nixon
and Yang 2012; Son et al. 2012; Salminen et al. 2013). Autophagy by the
lysosome is an alternative means to clear cellular debris such as misfold-
ed proteins, and can be mobilized in self-defense when the proteasome is
inhibited (Iwata et al. 2005; Ding et al. 2007; Rubinsztein et al. 2007; Janen
et al. 2010; Wong and Cuervo 2010). MG132, the toxin that we have used
to inhibit the proteasome, also inhibits lysosomal cathepsins (Lee and
Goldberg 1998). Thus, treatment with MG132 mimics both the proteaso-
mal and the autophagic stress of proteinopathies. In this respect it is sim-
ilar to lactacystin, a proteasome inhibitor that also inhibits cathepsin A
(Lee and Goldberg 1998; Aikawa et al. 2006).
In this review, we use the term “mild” to describe stressors that are
short enough in duration or low enough in dose to be sublethal. We use
the term “severe” to describe stressors that are long enough in duration
or high enough in dose to be lethal to some fraction of the cellular pop-
ulation. We envision that the response to stress in the human brain may
switch from enhanced resistance to increased vulnerability with a shift in
either stressor dose or duration. Our earlier work was based on the
hypothesis that adaptations to mild cellular stress may partly explain the
delayed onset and protracted nature of neurodegenerative conditions
(Leak et al. 2006; Leak and Zigmond 2007; Leak et al. 2008). We specu-
lated that endogenous defenses against stress may keep full-blown neu-
rodegenerative illnesses at bay in young individuals and may also brake
disease progression in those who do finally develop Parkinson’s or
Alzheimer’s disease in old age. Such favorable reactions elicited by low
dose stressors or eustress are defined as hormetic responses and are well
established in the toxicology literature (Calabrese 2008c; Giordano et al.
2008; Mattson 2008; Calabrese 2010). Hormesis can be viewed as the pro-
totypical homeostatic reaction to environmental fluctuations, in accor-
dance with the original definition of homeostasis by Claude Bernard and
Walter Cannon. The ability to respond dynamically to challenges that
threaten internal homeostasis is also described as plasticity and is more
evident in some cell types than others. With higher levels of stress, how-
ever, adaptive responses may fail and the response to subsequent chal-
lenges can be compromised. In the latter situation, pre-stressed cells
become sensitized to a second hit instead of protected. This toxic type of
response may predominate in vulnerable brain regions or in aged ani-
mals (Boger et al. 2010). The biphasic nature of the response to stress is
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reflected in the U-shaped, hormetic dose-response curves that are often
reported in toxicology. With some exceptions (Calabrese et al. 2007;
Calabrese 2008b), discussions of U-shaped dose response curves and
hormesis do not always include reference to a second hit. However, adap-
tation or sensitization to stress can be quantitatively measured by the
response of pre-stressed cells to a second challenge, as will be discussed
further below. If previously stressed cells are protected against a second
challenge relative to naïve cells, they are said to be preconditioned or in
a state of tolerance. On the other hand, if pre-stressed cells respond to
two hits with synergistic toxicity they are said to be sensitized to the sec-
ond challenge. In contrast, if two toxic hits are additive and not synergis-
tic, neither adaptation nor sensitization is at work and the first hit is, in a
sense, neutral, because it leaves behind cells that are as vulnerable to the
second hit as naïve cells. In short, a two hit protocol is extremely useful
to gauge both the direction and magnitude of the stress response.
Our long term goal is to characterize in detail the protein profile of
stressed, but adapted neuronal and glial cells and to contrast this profile
with cells that are sensitized to subsequent challenges. A better under-
standing of this “adaptive proteome” in the brain and how it responds to
homeostatic challenges might hasten the development of CNS pharma-
cotherapies or identify dietary/lifestyle changes that mimic these stress-
responses without causing any harm. Estimates place 15% of highly con-
served proteins in the stress responsive category (Kultz 2005); their abun-
dance and phylogenetic conservation can be viewed as a testament to
their importance in homeostasis. Stress responsive proteins include (1)
sensors to recognize perturbations, (2) transducers to amplify and inte-
grate signals and (3) effectors to counteract stress (Kultz 2005; Babar et
al. 2008). The effector proteins that battle challenges to homeostasis
include the antioxidant enzyme systems and folding chaperone machin-
ery as well as the prosurvival signaling cascades. Although these prosur-
vival effectors have often been observed to be lower in postmortem tissue
from Alzheimer’s and Parkinson’s victims, the occasions on which they
are higher in disease states are instructive. Well-established examples of
antioxidant defenses that are lowered early in the course of Parkinson’s
and Alzheimer’s disease include loss of the essential tripeptide glu-
tathione (Sofic et al. 1992; Sian et al. 1994; Calabrese et al. 2006; Baldeiras
et al. 2008; Zeevalk et al. 2008; Lloret et al. 2009; Martin and Teismann
2009; Johnson et al. 2012). Based on our two hit model of proteasome
inhibition in N2a cells (discussed below), catastrophic drops in glu-
tathione may reflect synergistic proteotoxicity within vulnerable cell
types. One should note that these prodeath cellular changes are not nec-
essarily maladaptive to the organism as a whole. It may benefit the organ-
ism to clear dysfunctional cells that are damaged beyond repair. Such
removal may decrease mutagenesis risk and preserve energy for other cel-
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lular systems that can be salvaged. In other words, even toxic responses to
stress may play an evolutionarily adaptive role under some circumstances.
In contrast to the loss in glutathione, some prosurvival molecules are
raised in the brains of victims of neurodegenerative diseases. Some of the
more enlightening examples of these changes will be discussed here. One
might speculate that increases in prosurvival molecules reflect those
remaining cells that have either successfully battled proteotoxic stress or
are able to prolong their lives by delaying the harmful sequelae of pro-
teotoxicity. It is also important to characterize regional variations in the
adaptive proteome in this context, as differences in endogenous defense
strategies across brain regions may underlie the topographic nature of
neurodegenerative disorders, where all neurons are not equally vulnera-
ble to inclusion formation and cell death (Mattson et al. 1989; Mattson
and Kater 1989; Braak et al. 2000; Braak et al. 2003; Posimo et al. 2013).
An example of regional differences in glutathione content has been pub-
lished by Mythri and colleagues (Mythri et al. 2011). Although glu-
tathione levels in the nigra are reduced in Parkinson’s disease, glu-
tathione levels are raised in the less vulnerable frontal cortex, caudate,
and putamen (Mythri et al. 2011). This increase in glutathione was accom-
panied by a decrease in the activity of gamma glutamyl transpeptidase,
the enzyme that breaks down glutathione. Glutathione peroxidase activi-
ty levels were also raised in the caudate and putamen, supporting the
hypothesis that more resilient brain regions are protected from oxidative
damage in Parkinson’s disease (Mythri et al. 2011). Another instructive
study of glutathione peroxidase 4 expression within neuromelanin-con-
taining cells in the nigra reveals an important caveat of these types of
experiments (Bellinger et al. 2011). In the Bellinger study, total glu-
tathione peroxidase 4 immunoreactivity was decreased in the substantia
nigra of Parkinson’s victims. However, when glutathione peroxidase 4
immunoreactivity was expressed relative to cell density, there was an
upregulation of glutathione peroxidase 4 levels within the remaining
nigral neurons in Parkinson’s brains. Thus, some previous studies that
have reported losses in prosurvival systems in neurodegenerative disor-
ders may actually reflect an overall loss in neuron number. Some studies
have dealt with this caveat by quantifying immunostaining intensities
within remaining neurons. One example of this type of study shows that
the ferroxidase ceruloplasmin is higher in the remaining CA1 hip-
pocampal neurons in Alzheimer’s brains (Loeffler et al. 2001).
Ceruloplasmin is a serum copper chaperone, but recent studies show that
it also plays a protective role in the central nervous system (Kaneko et al.
2008; Hineno et al. 2011; Texel et al. 2011). Ceruloplasmin concentrations
in the brain are increased in Alzheimer’s and Parkinson’s disease
(Loeffler et al. 1996). Given its ability to rise with stress in other human
conditions, the rise in ceruloplasmin in neurodegenerative diseases is not
R. K. Leak
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surprising and may reflect the endogenous defense capacities of the
human brain (Mezzetti et al. 1996; Mezzetti et al. 1998; Louro et al. 2000;
Taysi et al. 2002; Memisogullari and Bakan 2004; Chacko and Cheluvappa
2010).
Other defensive proteins that are upregulated in neurodegenerative
diseases include the well-studied heat shock family of proteins. The heat
shock response to stress is a primordial defense against denatured pro-
teins (Verbeke et al. 2001). Heat shock proteins battle apoptosis, refold
misfolded proteins, and escort damaged proteins to the proteasome or
lysosome for degradation (Kalia et al. 2010; Lanneau et al. 2010; Aridon et
al. 2011). One might therefore speculate that an endogenous rise in heat
shock proteins is a self-defense mechanism that slows down proteotoxici-
ty in proteinopathies. Heat shock protein 90 is raised in Parkinson’s dis-
ease and is colocalized with α-synuclein in Lewy bodies (Uryu et al. 2006).
Furthermore, heme oxygenase 1 (also known as heat shock protein 32) is
raised in hippocampal and cortical tissue in Alzheimer’s disease
(Schipper 2000; Schipper et al. 2006) and is also increased in astrocytes in
Parkinson’s disease (Schipper et al. 1998). In mild cognitive impairment,
a possible precursor to dementia, heat shock proteins 70 and 27 are both
increased in the inferior parietal lobule (Di Domenico et al. 2010).
Furthermore, heat shock protein 27 is raised in the nigrostriatal pathway
in Parkinson’s disease (Zhang et al. 2005). The major risk factor for neu-
rodegenerative diseases is aging. Although the induction of heat shock
proteins is impaired with aging, chaperones in general are increased with
aging (Fargnoli et al. 1990; Maiello et al. 1998; Soti and Csermely 2000;
Schultz et al. 2001; Walters et al. 2001; Gupte et al. 2010). For example,
heat shock proteins 40, 27, 60, 70, and constitutive heat shock protein 70
are known to increase in the aged central nervous system (Lee et al. 2000;
Lu et al. 2004). Clearly, different aspects of endogenous defenses can be
impaired or increased in individuals at risk for neurodegenerative dis-
eases or with full-blown disorders. Thus, both types of responses can coex-
ist in the same human brain, perhaps not the least because of striking
regional variations in vulnerability (Mattson et al. 1989; Mattson and
Kater 1989; Braak et al. 2000; Braak et al. 2003; Posimo et al. 2013).
Although it seems reasonable to speculate that rises in prosurvival
molecules in human neurodegenerative disorders slow down disease pro-
gression, this is not known for certain, as the human studies are correla-
tional and do not establish causation. Furthermore, the analysis of post-
mortem brain tissue is a cross-sectional snapshot of one moment in time.
As a result, we do not know whether changes in prosurvival proteins with-
in individual neurons are long term or transient in nature. Finally, it is
also not known how long stress-induced protection or sensitization can
linger in the human brain. Most of the answers to these questions come
from experimental model systems. The best way to experimentally
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address whether a response to stress is adaptive or toxic is to challenge
cells with a second hit and to quantify the degree of protection or sensi-
tization. As mentioned earlier, sublethal stress-induced protection against
subsequent challenges is known as preconditioning. The mechanisms
underlying preconditioning have been well defined in studies of ischemia
but are often neglected in the study of neurodegenerative diseases. Only
a small number of studies have considered the possibility of precondi-
tioning in models of neurodegenerative diseases and some of these will
be described here. First, Mark Mattson has proposed that dietary and
behavioral manipulations such as exercise and food restriction may pro-
tect against models of neurodegeneration by activating stress-responsive
pathways (Duan and Mattson 1999; Guo et al. 2000; Mattson et al. 2004;
Son et al. 2008). For example, dietary restriction increases levels of brain
derived neurotrophic factor, neurogenesis, and heat shock proteins
(Mattson et al. 2004). Mattson has further proposed that dietary phyto-
chemicals ingested from plants can precondition against multiple dis-
eases, including Parkinson’s and Alzheimer’s disease (Son et al. 2008).
From an evolutionary point of view, phytochemicals may activate stress-
responsive pathways because they are designed to repel insects, molds,
and even mammals. Two examples are nicotine and caffeine, both of
which have been associated with reduced risk for neurodegeneration in
epidemiological studies (Tan et al. 2003; Powers et al. 2008). Calabrese
and colleagues have argued that hormetic phytochemicals work through
vitagenes, genes which encode for heat shock proteins, sirtuin, and
thioredoxin (Calabrese et al. 2012). If phytochemicals continue to have
these effects for the long term, chronic adaptation may be possible in
humans. Second, dietary habits such as moderate alcohol consumption
are also associated with lower risks of Alzheimer’s disease and may also be
effective over the long term (Peters et al. 2008; Anstey et al. 2009). In sup-
port of this notion, ethanol can precondition against models of
Alzheimer’s disease (Mitchell et al. 2009; Collins et al. 2010). Other natu-
ral dietary compounds, such as the green tea polyphenol epigallocate-
chin-3-gallate and the red wine ingredient resveratrol have also been pro-
posed as preconditioning agents in Alzheimer’s and Parkinson’s disease
models (Raval et al. 2008; Tai and Truong 2010; Tang et al. 2011; Wu et al.
2012). Resveratrol is thought to protect cells in a sirtuin-dependent man-
ner (Farghali et al. 2012; Wu et al. 2012). Third, anesthetics induce toler-
ance against subsequent challenges in Alzheimer’s disease models and
raise levels of phosphorylated tau (Wei and Xie 2009; Tang et al. 2011).
Even β-amyloid itself can be used as a preconditioning tool against sub-
sequent challenges, such as glutamate excitotoxicity, by promoting endo-
cytosis of the NMDA receptor (Goto et al. 2006).
Another example of long term preconditioning in humans may be
the lifelong benefits of exercise. Exercise can be viewed as a natural, mild
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stress. Exercise is known to raise free radical content and can precondi-
tion against ischemia (Frasier et al. 2011; Powers et al. 2011; Zhang et al.
2011). Many studies have supported the long-term benefits of exercise in
humans, even in Alzheimer’s and Parkinson’s patients (Chen et al. 2005;
Xu et al. 2010; Erickson et al. 2012; Mayeux and Stern 2012; Fisher et al.
2013; Intlekofer and Cotman 2013; Winchester et al. 2013). Animal stud-
ies have also shown convincingly that exercise is protective in experi-
mental models of neurodegeneration (for some examples, see Adlard et
al. 2005; Nichol et al. 2009; Pothakos et al. 2009; Zigmond et al. 2009;
Gerecke et al. 2010; Vuckovic et al. 2010; Intlekofer and Cotman 2013;
Souza et al. 2013). The studies on the benefits of long term exercise,
dietary phytochemicals such as nicotine and caffeine, and moderate alco-
hol consumption all suggest that chronic adaptation to stress may be
achievable in humans. Furthermore, exercise is known to generate an
adaptive proteome. For example, we have observed that treadmill exer-
cise raises ceruloplasmin in primates and that levels of physical activity
are positively correlated with ceruloplasmin levels (Leak et al. 2012).
Despite its stress-responsive nature, ceruloplasmin has not been exten-
sively explored in connection with severe proteotoxic stress and brain
neuroprotection. Further studies on this protein are therefore warranted.
In a cellular Parkinson’s disease model, we have shown that sublethal
oxidative stress from 6-hydroxydopamine can precondition dopaminer-
gic cells against subsequent lethal exposures to higher concentrations of
the same toxin (Leak et al. 2006). The protection in this model was kinase
dependent, as inhibitors of ERK1/2, Akt, and JNK activation all attenuat-
ed the preconditioning-induced protection. Besides sublethal 6-hydroxy-
dopamine, another means of eliciting protection against lethal doses of
6-hydroxydopamine is by thrombin pretreatment in vivo (Cannon et al.
2005). Dopaminergic terminal loss in the striatum and ventricular
enlargement were both attenuated by thrombin preconditioning. Third,
hyperoxia preconditioning can protect animals against the behavioral
symptoms of 6-hydroxydopamine toxicity, such as apomorphine-induced
rotations and motor performance on the rotarod (Hamidi et al. 2012).
Fourth, preconditioning can also be elicited by the bacterial endotoxin
lipopolysaccharide. Lipopolysaccharide is well known to elicit inflamma-
tory responses but, in low concentrations, can precondition organotypic
midbrain cultures against subsequent lipopolysaccharide challenges
(Ding and Li 2008). Lipopolysaccharide preconditioning protected
against dopamine neuron loss as well as lactate dehydrogenase release in
this organotypic slice model. Lipopolysaccharide preconditioning also
prevented the microglial activation and tumor necrosis factor-α release in
response to the second, higher concentration of lipopolysaccaride. In
addition to these inflammation-suppressing functions of precondition-
ing, homeostatic crosstalk between endoplasmic reticulum stress and
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autophagy may also mediate the benefits of preconditioning in Drosophila
and mouse Parkinson’s disease models (Fouillet et al. 2012; Matus et al.
2012). In these studies, inhibition of autophagy was found to impair
endoplasmic reticulum stress-induced protection. Matus and colleagues
have recently reviewed these hormetic responses to protein-misfolding
stress (Matus et al. 2012). Fifth, activation of the antioxidant response ele-
ment by endoplasmic reticulum stress inducers can also precondition
against 6-hydroxydopamine toxicity (Hara et al. 2011). Sixth, low dose
methamphetamine challenges can protect dopaminergic cells against 6-
hydroxydopamine toxicity (El Ayadi and Zigmond 2011). Finally, in vitro
studies also provide evidence that heat shock can precondition against 1-
methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), another well-established
model of Parkinson’s disease (Quigney et al. 2003; Fan et al. 2005). These
studies, while not numerous, reveal that preconditioning can indeed
occur in models of neurodegenerative diseases.
In contrast to the small numbers of studies on preconditioning in
neurodegeneration, several seminal papers on short duration ischemic
episodes initiated a flood of investigations on preconditioning in stroke
models (Murry et al. 1986; Kitagawa et al. 1990; Kirino et al. 1991; Liu et
al. 1992; Kirino 2002; Dirnagl et al. 2003). These studies consistently
showed that short, sublethal ischemic episodes elicit tolerance of subse-
quent, longer duration ischemic attacks that would otherwise be lethal.
As argued by Valina Dawson, ischemic preconditioning offers a way to
“mine for survival genes” (Dawson and Dawson 2006) and has been a pro-
ductive field of research for many decades. Ischemic preconditioning also
has translational potential; remote ischemic preconditioning of an arm
or leg with a tightened blood pressure cuff may protect distant organs
from ischemic events such as stroke and cardiac bypass surgery
(Fairbanks and Brambrink 2010; Candilio et al. 2011). The state of our
knowledge on ischemic preconditioning has been discussed in many
recent reviews (Dirnagl and Meisel 2008; Della-Morte et al. 2012; Kitagawa
2012; Prabhakar and Semenza 2012; Thompson et al. 2012) and will not
be described further here.
As mentioned above, if the stressor is severe, it can exacerbate the
toxic response to future insults and result in greater than additive cell
loss. For example, previous exposures to thromboembolic events can
combine with a subsequent ischemic insult to produce larger areas of
ischemic injury (Dietrich et al. 1999; Danton et al. 2002). In the field of
neurodegeneration, the synergistic toxicity of multiple challenges is the
subject of the “two hit” or “dual hit” hypothesis (Zhu et al. 2004; Carvey et
al. 2006; Manning-Bog and Langston 2007; Sulzer 2007; Zhu et al. 2007;
Weidong et al. 2009; Boger et al. 2010; Gao and Hong 2011; Unnithan et
al. 2012). A few reports of dual-hit insults in Parkinson’s and Alzheimer’s
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disease will be described below. First, Carvey and Di Monte have discussed
the dual hit concept with reference to Parkinson’s disease in that suffi-
cient cell loss to elicit symptoms may require multiple stress exposures
(Di Monte et al. 2002; Ling et al. 2004b). For example, toxic environmen-
tal agents might interact with endogenous factors such as α-synuclein and
aging. Indeed, gene-environment interactions are particularly relevant to
the two hit hypothesis (Gao and Hong 2011) and can be studied by fus-
ing animal models (Manning-Bog and Langston 2007). Genetic disrup-
tions that result in fewer dopamine neurons at birth may also result in
Parkinsonian symptoms when combined with age-related neuronal attri-
tion (Weidong et al. 2009). Other models of the two hit hypothesis have
examined loss in trophic factors such as glial cell derived neurotrophic
factor (GDNF) and its impact on the response to aging and to metham-
phetamine challenges (Boger et al. 2010). As expected, genetic reduc-
tions in GDNF exacerbate age-related changes in dopaminergic systems
and increase vulnerability to methamphetamine. Several studies have
examined the two hit hypothesis in the context of inflammatory changes
to the brain. The authors of these studies consistently report that the pes-
ticide rotenone or the neurotoxin MPTP can both combine with the
inflammogen lipopolysaccharide to elicit synergistic neurotoxicity in
dopamine neurons (Gao et al. 2003a; Gao et al. 2003b; Ling et al. 2004a).
Dopamine oxidation and mitochondrial dysfunction have also been sug-
gested to combine with loss of function gene mutations or autophagic
self-degradation to underlie cell death in Parkinson’s disease (Sulzer
2007). Smith and colleagues have put forth a two hit hypothesis for
Alzheimer’s disease in that oxidative stress and mitogenic dysregulation
may combine to increase risk for Alzheimer’s pathology (Zhu et al. 2001;
Zhu et al. 2004; Zhu et al. 2007). In their model, oxidative stress and
abnormalities in mitotic signaling can both initiate pathology, but both
must be present to propagate the full extent of the pathology. A multiple
hit model of changes in tau function has also been suggested to promote
tau assembly (DeTure et al. 2006). Furthermore, traumatic brain injury
has been hypothesized to predispose individuals to both Parkinson’s and
Alzheimer’s disease (Kiraly and Kiraly 2007). Finally, a two hit study from
the stroke literature is particularly edifying (Qiao et al. 2009). In this study
by Tuor and colleagues, a 40 min stroke resulting in focal necrosis was
combined with a 60 min stroke three days later. Proximal to the ischemic
core, where loss of blood flow was the most severe, the damage exceeded
that of the first insult, whereas distally, there was tolerance to the insult.
These findings reveal that adaptation and sensitization can occur within
the same brain and show elegantly that the direction of the response
depends on the magnitude of the insult.
The two hit terminology has not generally been applied to studies of
preconditioning although preconditioning protocols also apply two
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sequential stressors. The word ‘hit’ is not typically used in reference to
sublethal stress even though it elicits transient damage (for an example,
see Dembinski et al. 2006). Sublethal preconditioning stimuli also
increase reactive oxygen species and activate the caspase cascade
(McLaughlin et al. 2003; Thompson et al. 2012). Without sublethal injury,
there would be no stress response because the sensors would not recog-
nize any perturbations. Before setting semantic issues aside, we argue
here that the two hit hypothesis should, by definition, encompass any pro-
tocol that involves two hits, be they sublethal or lethal, and that the
hypothesis must account for the biphasic nature of stress responses.
Therefore, we propose that the response to two hits can involve the fol-
lowing: 1) preconditioning-style adaptations following sublethal stressor
hits, 2) additive toxic responses to two severe stressor hits in which the
first hit does not change the response to the second hit, 3) synergistic
toxic responses to two severe stressor hits in which the first hit magnifies
the response to the second hit, and 4) adaptive responses to severe stress
so that the impact of a second hit is blunted in the cells that manage to
survive the first hit. To explore some of these possibilities, below we
describe our recent work investigating responses to proteotoxicity in var-
ious two hit cellular models. We begin with a description of adaptations
to chronic low dose proteotoxic challenges. A high-throughput two hit
model of synergistic neurodegeneration is also presented. Finally, we
summarize our recent findings that astrocytes, a glial cell type well known
for stress-induced plasticity, can adapt to proteotoxic stress delivered at a
high enough concentration to kill half the population. This was the first
demonstration that the glial survivors of severe proteotoxic stress are
more resistant than naïve cells. The mechanisms underlying the adapta-
tions and sensitization are also presented.
EVEN LONG-TERM STRESS CAN ELICIT ADAPTATIONS
As mentioned above, neurodegenerative conditions are characterized
by inhibition of the normal role of the proteasome. Indeed, the chronic
nature of neurodegenerative conditions raises the possibility that dis-
eased brains are exposed to proteotoxic stress for an extended time-
frame. Of course, Selye had argued that chronic stress weakens defenses.
Nonetheless, we wondered if cells are able to adapt to chronic stress if the
dose is low enough. If this was true, mild stress-induced plasticity might
explain why neurodegenerative conditions are so slow to progress despite
evidence of long-term proteotoxicity.
Although Parkinson’s disease involves degeneration of multiple brain
regions, such as noradrenergic (Forno 1996; Gesi et al. 2000), serotoner-
gic (Halliday et al. 1990; Gai et al. 1992; Politis et al. 2012), and hypocre-
tin/orexin systems (Fronczek et al. 2007; Thannickal et al. 2007), the
motor deficits are largely attributed to massive dopaminergic cell loss in
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the nigrostriatal tract. Parkinson’s disease is also characterized by its late
age of onset and progressive nature, suggesting that endogenous adapta-
tions may be hard at work. In order to test the hypothesis that cells can
adapt to chronic stress in a dopaminergic model, PC12 cells were exposed
to long durations (14 days - 6 months) of the proteasome inhibitor
MG132 (Leak et al. 2008). In our model, MG132 (0.1 μM) effectively
reduced chymotrypsin proteasome activity by 47%. Furthermore, there
was a statistical trend towards higher levels of ubiquitin-conjugated pro-
teins with MG132 treatment. These findings suggest that MG132 was pro-
teotoxic in this model. However, no impact of chronic MG132 on overt
morphology or tyrosine hydroxylase expression was observed. Tyrosine
hydroxylase is the rate-limiting enzyme for dopamine biosynthesis. We
also measured viability at 4-5 day intervals for two weeks after initiation of
MG132 treatment and found no change. MG132 (0.1 μM) was left in the
media at all times for up to 6 months. Viability was measured within two
days after plating cells throughout this entire procedure. We discovered
that chronic pretreatment with 0.1 μM MG132 did indeed protect against
subsequent challenges. Fourteen days or longer exposure to sublethal
MG132 protected against either 6-hydroxydopamine or higher-dose
MG132 (40 μM). Protection in this system was verified by two independ-
ent assays for cell viability: the Cell Titer Glo assay for ATP and counts of
Hoechst-stained nuclei. We typically perform at least two viability assays in
order to reduce the likelihood of false positives and to measure protec-
tion of both cell numbers and metabolic activity. This helps us ascertain
the impact of treatments on cellular structures as well as their function.
However, a potential confound of our interpretation that chronic MG132
was protective would be if MG132 decreased activity of the dopamine
transporter that shuttles 6-hydroxydopamine into the cytoplasm from the
extracellular medium. In other words, we were concerned that the rise in
viability in chronically stressed cells might be an artifact of reduced influx
of the 6-hydroxydopamine toxin. In contrast to this expectation, we
observed a 36% rise in dopamine transporter activity after chronic treat-
ment with MG132, not a fall. This suggested that the pre-stressed cells
were protected despite slightly greater exposure to 6-hydroxydopamine.
Notably, when MG132 was removed from the media for more than two
weeks, the protection disappeared, suggesting that the stress had to be
continuous to elicit an adaptive response. Conversely, this low concentra-
tion of MG132 was not sufficient to elicit protection if administered for
less than two weeks. Taken together, all of these observations are consis-
tent with the hypothesis that dopaminergic cells have the capacity to
adapt to chronic sublethal stress but that the protection disappears when
the stressful stimulus is removed.
Next we proceeded to examine the mechanism underlying long term
adaptive defenses. First, we scrutizined the role of the ubiquitous thiol
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glutathione in this model. Thiol defenses are so important to cells that
glutathione is present in millimolar concentrations in most tissues
(Cooper and Kristal 1997; Wilson 1997; Dringen 2000; Pompella et al.
2003; Pocernich and Butterfield 2011). Proteotoxicity and oxidative
stress are inextricably intertwined in neurodegenerative conditions
because oxidized proteins can become misfolded and must be degraded
by clearance systems such as the proteasome. We initially speculated that
glutathione would stave off the negative impact of chronic proteotoxic
stress. Thus, we hypothesized that inhibiting glutathione synthesis would
abolish or attenuate the stress-induced protection against 6-hydroxy-
dopamine. In contrast to this expectation, inhibition of glutathione syn-
thesis with buthionine sulfoximine exacerbated 6-hydroxydopamine tox-
icity to the same degree in naïve cells and cells treated with chronic
MG132 and did not attenuate the MG132-induced protection at all.
Chronic MG132 also did not raise glutathione levels. This suggested that
glutathione defenses were not responsible for the adaptation to long
term MG132.
As a result of these negative findings, we proceeded to examine levels
of other antioxidant molecules and folding chaperones. We found an
increase in CuZn superoxide dismutase enzymatic activity and protein
levels with chronic MG132. In contrast, a small rise in Mn superoxide dis-
mutase protein levels was not accompanied by a parallel rise in enzyme
activity. Superoxide dismutases catalyze the dismutation of superoxide
into hydrogen peroxide and oxygen. Catalase and heat shock protein 70
levels were also raised by chronic MG132. Catalase aids the breakdown of
hydrogen peroxide and thus may act in conjunction with the superoxide
dismutase enzymes. Heat shock protein 70 actively battles apoptosis in
addition to its chaperone functions and is thought to be protective
against neurodegeneration (Koren et al. 2009; Nagai et al. 2010; Witt
2010; Aridon et al. 2011; Silver and Noble 2012). We decided to focus on
the change in CuZn superoxide dismutase because previous investiga-
tions had shown that CuZn superoxide dismutase overexpression is pro-
tective in models of Parkinson’s disease whereas deficiencies in this pro-
tein exacerbate dopaminergic neurodegeneration (Przedborski et al.
1992; Asanuma et al. 1998; Barkats et al. 2002; Sturtz and Culotta 2002;
Van Remmen et al. 2004; Barkats et al. 2006; Wang et al. 2006). Notably,
CuZnSOD levels are lowered in Parkinson’s and Alzheimer’s patients
(Boll et al. 2008; Torsdottir et al. 2010), and CuZnSOD is found in Lewy
bodies (Nishiyama et al. 1995). We therefore hypothesized that knock-
down of CuZn superoxide dismutase with RNA interference would atten-
uate the MG132-induced protection against 6-hydroxydopamine. As
expected, CuZn superoxide dismutase knockdown with either of two
short interfering RNA (siRNA) sequences attenuated MG132-induced
protection. Using two independent siRNA sequences in place of one
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sequence alone reduced the likelihood of false positive results from non-
specific effects of RNA interference. Taken together, these findings
revealed multiple adaptive changes in stressed cells and showed that
CuZn superoxide dismutase was responsible for long term stress-induced
protection against oxidative toxicity.
In summary, these studies describe the protective nature of chronic
but mild proteotoxic stress. The protection lasted for at least 6 months
(the latest timepoint we tested), but removal of the stimulus caused loss
of defenses. Adaptive proteins such as anti-apoptotic chaperones and
antioxidant enzymes were raised by chronic stress and CuZn superoxide
dismutase mediated protection of dopaminergic cells against oxidative
toxicity. It must be acknowledged here that our definition of chronic falls
short of the decade-long march of neurodegeneration in Parkinson’s and
Alzheimer’s disease. The only conceivable model systems in which
decades-long insults might be applied are the nonhuman primates.
Whether mild, low dose proteotoxic stress can protect the primate brain
for the truly long term remains to be seen. Second, although they express
tyrosine hydroxylase, PC12 cells are not always predictive of dopaminer-
gic neurons because PC12 cells originate from the adrenal gland and not
the brain. Although PC12 cells can be differentiated to a neuronal phe-
notype, differentiated PC12 cells are unsuitable for the long term studies
conducted here because they begin to die. For our next high-throughput
cellular model, we switched to a neuroblastoma cell line, N2a, which orig-
inates from the mouse spinal cord. Although N2a cells are not dopamin-
ergic, Parkinson’s disease is now well known to extend beyond the ventral
midbrain, as mentioned earlier. Many extranigral brain regions, includ-
ing the spinal cord, are affected with synuclein inclusions (Braak et al.
2002; Braak et al. 2003; Del Tredici and Braak 2012). In the studies dis-
cussed below, we examined the N2a response to acute, severe proteotox-
ic stress in a cellular model of synergistic neurodegeneration.
CELLS CAN BE SENSITIZED TO INJURY BY SEVERE STRESS
Although stressors that potentiate the response to subsequent chal-
lenges may occur decades prior to the second hit, two hits may also occur
in rapid succession, such as exposure to toxicants in careers in agriculture
or industry. Many agricultural workers, for example, are exposed to pes-
ticides and herbicides on a daily basis. Some of these pulsatile challenges
to humans may elicit oxidative damage and protein misfolding. In sup-
port of this notion, pesticide and herbicide exposures increase the risk
for Parkinson’s disease and cause protein aggregations and cell death in
animal models (Liou et al. 1997; Betarbet et al. 2000; Alam and Schmidt
2002; Manning-Bog et al. 2002; McCormack et al. 2002; Franco et al. 2010;
Tanner et al. 2011). We hypothesized that synergistic responses to dual
proteotoxic challenges should be dose dependent and only elicited by
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severe stress, such as high concentrations of MG132. In support of this
hypothesis, lethal, but not sublethal concentrations of MG132 were found
to synergize in their negative impact on N2a viability when administered
24 hours apart (Unnithan et al. 2012). Three independent and unbiased
viability assays, conducted on the third day, illustrated this effect. For
assaying viability in a high-throughput manner, we stained the nucleus
and cytoplasm with a combination of two infrared stains (DRAQ5 and
Sapphire) and measured levels of the cytoskeletal protein α-tubulin with
immunocytochemistry. The third viability assay, Cell Titer Glo, measured
ATP levels. Interestingly, the Cell Titer Glo assay demonstrated that sub-
lethal concentrations of MG132 raised ATP without a parallel change in
cell numbers. This favorable metabolic reaction to low level proteotoxic
stress may allow slightly stressed cells to battle sublethal injury more effec-
tively and is an example of hormesis. As hypothesized, higher concentra-
tions of MG132 elicited cell loss and increased the toxic response to a sec-
ond MG132 hit by all three viability assays. Low or subtoxic concentra-
tions of MG132 did not elicit this synergistic response. Toxic, but not
subtoxic concentrations of MG132 greatly raised ubiquitin-conjugated
proteins in this model, suggesting that higher concentrations of MG132
effectively hindered the clearance of misfolded proteins (Fig. 1).
Adaptive responses to low level stress in our dopaminergic model of
the previous section included rises in several antioxidant proteins and the
anti-apoptotic folding chaperone heat shock protein 70. Conversely, we
expected toxic responses to severe stress to involve loss of antioxidant and
chaperone defenses. Contrary to these hypotheses, we found no loss in
heat shock protein 70 with toxic MG132 concentrations. In addition,
toxic, but not subtoxic MG132 elicited a rise in ceruloplasmin, not a loss
(Fig. 1). Our data showing an MG132-induced rise in ceruloplasmin in
neuronal cells is consistent with previous studies that it increases with
stress (Mezzetti et al. 1996; Mezzetti et al. 1998; Louro et al. 2000; Taysi et
al. 2002; Memisogullari and Bakan 2004; Chacko and Cheluvappa 2010)
and demonstrate that this response can be elicited by proteotoxicity even
when the stress is severe.
Next we examined whether toxic MG132 would elicit loss of
autophagic markers, because concomitant failure of autophagic and pro-
teasome defenses might underlie the synergistic toxicity of two MG132
hits. However, toxic concentrations of MG132 raised proteins involved in
chaperone-mediated autophagy such as heat shock cognate 70 (Hsc70)
and the lysosome-associated membrane protein type-2a (LAMP2a). These
responses again reflect adaptive responses to severe proteotoxic stress,
not toxic responses to stress (Fig. 1). The notion that the chaperone-
mediate autophagy markers reflect cellular engagement in self-defense
was supported by the finding that ammonium chloride, an inhibitor of
autophagic protease activity (Kaushik and Cuervo 2009), increased the
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toxicity of both single and dual hits of MG132 in our model. Thus, cells
exposed to toxic concentrations of proteasome inhibitors may rely on
autophagy as an alternative mechanism to clear cellular debris. Of course,
adaptive responses such as rises in ceruloplasmin or autophagic markers
failed to explain why two toxic MG132 hits were synergistic in nature. We
therefore proceeded to test the hypothesis that loss of thiol defenses
underlay the toxic impact of two hits.
In contrast to the rises in autophagic proteins and ceruloplasmin, we
found that two hits elicited a synergistic loss of glutathione. The response
of glutathione to two hits therefore paralleled the synergistic loss of via-
bility and supported the hypothesis that loss of thiol defenses might
underlie the toxicity of two hits (Fig. 1). As a result of these findings, we
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FIGURE 1. Misfolded proteins are tagged with an ubiquitin tail, linearized, and fed through one end
of the barrel-shaped proteasome. Peptides exit the other end of the proteasome and are further
degraded by cytoplasmic peptidases into amino acids for recycling into fresh proteins. Stress on the
proteasome, such as that induced by proteasome inhibitors, causes the buildup of misfolded proteins
that can no longer be degraded. In N2a cells treated with high concentrations of the proteasome
inhibitor MG132, two types of responses are elicited in response to the reduced clearance of dam-
aged proteins. A rise in the antioxidant ceruloplasmin and the chaperone-mediated autophagy pro-
teins lysosome-associated membrane protein type-2a (LAMP2a) and heat shock cognate 70 (Hsc70)
may serve to defend the cell. Inhibiting autophagic defenses increases the toxicity of both single and
dual MG132 hits in this model, suggesting that cells use autophagy as an alternative clearance mech-
anism when the proteasome is inhibited. Cells also respond to dual hits of severe proteotoxicity with
a synergistic loss in glutathione (GSH) defenses. This loss of GSH may increase oxidative toxicity and
enhance cell death. 
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examined whether raising glutathione levels would protect the N2a cells
against two toxic hits of MG132. The glutathione precursor N-acetyl cys-
teine prevented glutathione loss and almost completely abolished the
toxic response to two MG132 hits by all three viability assays. N-acetyl cys-
teine is an over-the-counter supplement well known to be protective in
animal models (for some examples, see Perry et al. 1985; Martinez
Banaclocha 2000; Pocernich et al. 2000; Farr et al. 2003; Fu et al. 2006;
Tucker et al. 2006; Sharma et al. 2007; Clark et al. 2010). It has even been
shown to benefit cognitive status in Alzheimer’s patients (Adair et al.
2001). N-acetyl cysteine is therefore currently being tested in clinical tri-
als of Parkinson’s disease (Clinicaltrials.gov ID: NCT01470027). Our find-
ings are consistent with a protective effect of N-acetyl cysteine against pro-
teinopathies, even when the proteotoxic stress is high in concentration
and unremitting in nature.
In summary, the response of neuronal cells to two MG132 hits reveals
an exquisite dose-sensitivity of synergistic effects. Low concentrations of
MG132 did not elicit synergistic toxicity; only severely toxic concentra-
tions of MG132 potentiated the response to the second hit. Despite the
toxic effects of high concentrations of MG132, highly stressed cells
nonetheless appeared to raise adaptive defenses in the form of autophag-
ic markers and ceruloplasmin (Fig. 1). One might speculate that stressed
cells would be even worse off without such defenses. This speculation is
supported by our observation that the toxicity of MG132 was increased
with an autophagy inhibitor. These studies showed for the first time that
the two hit neurodegenerative phenomenon can be extended to protein-
misfolding stress from proteasome inhibition. Furthermore, the data on
glutathione support the classic notion that oxidative and proteotoxic
stressors propel and propagate each other. Oxidative stress has been asso-
ciated with neurodegenerative proteinopathies for many decades ever
since Denham Harman drew attention to free radicals in aging in the
1950s (Harman 1956; Floyd and Hensley 2002; Harman 2006, 2009).
A few caveats of our neuroblastoma studies are worth mentioning
here. Our N2a studies of two proteotoxic hits were extremely short in
duration compared to the decades-long exposure to stress in human neu-
rodegenerative conditions. Our protocol is better suited to model the
toxic impact of rapid, successive hits of proteotoxic stress. Second, the
protein profile and concentration of reactive oxygen species in tumor
cells is often different from that of normal cells, especially when con-
trasted to differentiated cells that have exited the cell cycle some time
ago. Studies on immortalized lines cannot fully recapitulate the highly
heterogenous and differentiated pool of neurons in the brain. Primary
cultures are therefore probably more predictive of in vivo brain function
and were used in the next series of experiments. Because we had
observed a number of defensive responses to severe proteotoxic stress in
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N2a cells, we wondered whether primary astrocytes might adapt to high
dose proteotoxic stress. A previous study by Friedman and colleagues pro-
vides precedence to examine the protective impact of severe stress. In
that study, exposure to a moderately toxic hit of glutamate (eliciting 30%
cell loss) protected hippocampal neurons against exposure to a lethal
glutamate challenge 7 days later (Friedman and Segal 2010).
ASTROCYTES CAN ADAPT TO SEVERE STRESS
Thus far we had shown that dopaminergic cells can adapt to low level
proteotoxic stress in a CuZn superoxide dismutase-dependent and glu-
tathione-independent manner but that neuronal cells cannot survive
multiple bouts of high level proteotoxic stress because of catastrophic glu-
tathione loss. Notably, highly stressed neuronal cells still responded to
toxic MG132 with some adaptations, such as a rise in autophagic markers
and ceruloplasmin. All of these findings led us to wonder whether severe
proteotoxicity would elicit adaptations in cells known for their stress
resistance, astrocytes (Shao and McCarthy 1994). Astrocytes are well
known to interact with neighboring neurons, providing them with troph-
ic support and metabolic precursors such as lactate (Westergaard et al.
1995; Rathbone et al. 1999; Benarroch 2005; Barres 2008). Furthermore,
astrocytes probably serve as sentinels, as they express many types of neu-
rotransmitter receptors (Fuller et al. 2010; Verkhratsky et al. 2012).
Astrocytes are also critical for the production of glutathione in the brain
(Dringen et al. 2000). In Parkinson’s disease, astrocytes in the amygdala,
septum, cortex, thalamus, and striatum become immunoreactive for the
neuronal protein α-synuclein (Wakabayashi et al. 2000; Braak et al. 2007).
These findings support the hypothesis that astrocytes engulf α-synuclein
from the extracellular space through endocytosis to protect neighboring
neurons (Lee et al. 2010). Furthermore, astrocytes are also known to
engulf extracellular β-amyloid (Wyss-Coray et al. 2003). Because of their
plasticity and critical roles in maintaining neuronal viability, astrocytes
have been proposed to define homeostasis in the central nervous system
(Parpura et al. 2012).
Given the plasticity of astrocytes, we wondered whether adaptive
astrocytic responses could be elicited even with LC50 concentrations of
MG132 that were lethal to half the cellular population. To our knowledge
this question had not been answered in astrocytes before, although pre-
vious studies had shown that astrocytes can adapt to sublethal stressors
(Rajapakse et al. 2003; Calabrese 2008a; Chu et al. 2010; Du et al. 2010; Du
et al. 2011; Johnsen and Murphy 2011). In our model, we delivered two
hits of toxic concentrations of MG132 one day apart to primary cortical
astrocytes (Titler et al. 2013). Cells were assayed for viability on the third
day by counting the remaining Hoechst-stained nuclei and measuring
ATP. Toxic MG132 concentrations that killed approximately half the pop-
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ulation of astrocytes did render the remaining cells resistant to a second
MG132 hit. In other words, the toxicity of two hits was neither additive
nor synergistic and the response to the second hit was blocked. Both cell
count and ATP level viability assays verified that pre-stressed astrocytes
were protected against a second hit. Although the cell count data con-
firmed the lethal nature of the first hit, the ATP assay actually revealed a
slightly different pattern than cell counts. That is, the first hit did not elic-
it any ATP loss as it had loss of cell numbers; ATP output per cell had
risen instead. Second, the first hit completely prevented the usual ATP
loss in response to the second, higher dose challenge. The ATP dose-
response curve therefore looked very similar to a traditional precondi-
tioning curve with sublethal stress protecting against a second, otherwise
lethal challenge. Because the pre-stressed cells were protected against
ATP loss in response to a second MG132 challenge, we concluded that
astrocytes exhibit active metabolic adaptations in response to severe pro-
teotoxic stress. The rise in ATP output with the first hit may help fuel anti-
apoptotic signaling cascades and preserve homeostasis.
As a potential confound to our interpretations on active astrocytic
adaptations, we initially wondered whether the first MG132 hit was simply
leaving behind astrocytes that were refractory to the toxin and therefore
also unresponsive to a second hit. If this was the case, we could not claim
that astrocytes mounted any adaptations to MG132. Alternatively, a second
MG132 hit could continue to have an impact on the proteasome in pre-
stressed cells even though it did not lead to additional cell death. We tried
to distinguish between these two possibilities by assaying for ubiquitin-con-
jugated proteins. We found that two hits of MG132 caused a synergistic rise
in ubiquitin-conjugated proteins (Fig. 2). This finding was incompatible
with the hypothesis that the remaining cells were simply refractory to
MG132. Even though the downstream impact of proteotoxic stress on cell
viability itself was abrogated, these data demonstrate that the stress on the
proteasome itself was not prevented. The potentiation of this proteasomal
response verifies the continued impact of MG132 in the survivors of the
first hit and also reflects the severity of the proteotoxicity.
In order to probe for adaptive rises in pro-survival molecules in
stressed astrocytes, we measured heat shock protein 70 and heme oxy-
genase 1. Heme oxygenase 1 degrades heme into biliverdin and carbon
monoxide (Grochot-Przeczek et al. 2012). Astrocytes express high levels
of this protein, perhaps reflecting their inherent resilience (Dwyer et al.
1995). Both heat shock protein 70 and heme oxygenase 1 were raised by
MG132, as expected from cells that are attempting to battle toxicity (Fig.
2). We also probed for glutathione levels in this model, and discovered
that pre-stressed astrocytes failed to respond to the second hit with the
usual glutathione loss, unlike naïve astrocytes challenged with high dose
MG132. In other words, glutathione levels following the MG132 chal-
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lenge were higher in pre-stressed astrocytes than in naïve controls. This
finding suggested that severely stressed astrocytes might use thiol defens-
es to protect themselves against future insults. Consistent with this
hypothesis, depletion of glutathione stores with buthionine sulfoximine
unmasked the cumulative impact of two hits; pretreated astrocytes now
became vulnerable to the second MG132 hit and responded with addi-
tional cell loss. The unmasking of the vulnerability to two hits following
glutathione depletion was also inconsistent with the notion that the first
MG132 hit simply left behind cells that were unresponsive to the poison.
As in the N2a two hit model, the findings reveal that antioxidant defens-
es help defend cells against proteotoxic stress. However, astrocytes and
the neuronal N2a cells responded to severe proteotoxicity in opposite
fashion. The response to the second proteotoxic hit was blocked in astro-
cytes but potentiated in N2a cells. We do not claim here that neuronal
cells only respond to dual challenges with synergistic toxicity or that only
astrocytes can adapt to severe stress. Instead, we have preliminary data in
primary cortical cultures that neurons are able to adapt to severe oxida-
tive stress from hydrogen peroxide pretreatment. Thus, whether severe
stress elicits adaptations or exacerbates further insults may depend on
the nature of the stress as well as the specific cell type, in addition to dose
and duration.
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FIGURE 2. Stress on the proteasome, in the form on inhibition of its normal proteolytic function,
increases the cellular burden of damaged proteins. Astrocytes respond to such proteasome inhibition
with a rise in the anti-apoptotic heat shock protein 70 (Hsp70). Numerous studies reveal that Hsp70
refolds misfolded proteins or enhances their degradation by the proteasome. A parallel rise in heme
oxygenase 1 (HO-1), a generally protective phase 2 enzyme, is also apparent. Astrocytes respond to
severe proteotoxicity with glutathione (GSH) loss, unless they have been pre-stressed with MG132, in
which case GSH levels are restored. This thiol adaptation serves to increase the number of viable
astrocytes and is accompanied by a rise in ATP. Pre-stressed astrocytes are thus both structurally and
functionally protected against further proteotoxicity. 
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In summary, astrocytes are a highly plastic cell type that can adapt to
stress even when it is toxic enough to kill half the population. The astro-
cytes that survive the initial hit are less, not more, vulnerable to further
proteotoxicity and have higher levels of glutathione upon the second hit
(Fig. 2). We speculate that astrocytes that are exposed to similarly severe
protein-misfolding stress in the human brain may fulfill their roles as neu-
rosupportive cells better than if they had no such defenses. As mentioned
above, astrocytes and neurons are well known to interact in the brain,
probably in conjunction with oligodendrocytes (Amaral et al. 2013). It
remains to be determined whether stressed astrocytes provide increased
trophic, metabolic, or antioxidant support for neighboring neurons or
whether stressed astrocytes engulf more misfolded proteins in proteotox-
ic conditions. Many have argued instead that activated astrocytes neglect
their neurosupportive roles, particularly in the presence of chronic
inflammation (Fuller et al. 2010). Thus, examinations of the protective or
toxic impact of severe proteotoxic stress on neuronal-astrocytic interac-
tions are highly warranted.
CONCLUSIONS
The mammalian brain enjoys manifold robust defenses. Even the sim-
ple observation that a large fraction of dopamine must be lost before
movement deficits emerge reflects the impressive compensatory adapta-
tions of the human brain (Hornykiewicz 1975; Zigmond et al. 1990;
Hornykiewicz 1998). Another form of adaptation is the ability to raise
anti-apoptotic proteins in response to stress. The studies detailed in this
review, as well as many others not discussed here, have slowly begun to
define this adaptive proteome. Our studies add to this body of work by
specifically revealing that the ubiquitous tripeptide glutathione is respon-
sible for adaptation against severe proteotoxicity. Conversely, when it is
reduced in levels, a lack in glutathione is responsible for synergistic pro-
teotoxicity.
As mentioned above, the long term goal of our studies is to charac-
terize the adaptive proteome so that it can be mimicked with pharmaco-
logical tools. Clinical preconditioning with pharmacotherapies is not
unprecedented or futuristic. Many FDA approved agents such as aspirin,
isoflurane, and statins are already thought to precondition against
ischemia (Gidday 2010). Defining the molecular targets of precondition-
ing and the effectors to counteract stress may also guide studies on
lifestyle and dietary factors that elicit a naturally therapeutic protein pro-
file. However, all the findings presented must be examined in further
detail in whole animals and over longer timeframes. Even partial inhibi-
tion of the proteasome for many months does not recapitulate the full
extent of the pathophysiology of neurodegenerative disorders. More
chronic models than presented here are therefore required to rigorously
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test the hypothesis that the cells that remain behind after neurodegener-
ation has commenced are either resistant or sensitized to further toxicity.
Studies of this nature would build upon previous in vivo reports showing
that repeated stressors can provide persistent protection against
ischemia/reperfusion injury (Hoshida et al. 2002). Bearing these impor-
tant gaps in our knowledge and the experimental caveats in mind, we pre-
dict that both neurons and glia in vivo will react to severe stress in a way
that deeply affects their response to subsequent challenges, but that the
response will depend on dose, duration, and perhaps brain region
(Mattson et al. 1989; Mattson and Kater 1989; Braak et al. 2000; Braak et
al. 2003; Posimo et al. 2013). More specifically, we propose that distinct
adaptations and vulnerabilities to proteotoxic stress across different brain
regions may underlie the signature topographies of protein inclusions in
neurodegenerative diseases.
Finally, the two hit model is probably a simplification of the injuries
that occur in neurodegenerative conditions because the diseased human
brain may be exposed to a rolling landscape of hits, and not just two
sequential stressors. Furthermore, some stressors may not even appear as
a hit because they are not transient, but chronic in nature. Nevertheless,
the two hit treatment protocol with MG132 is a useful tool to probe
whether proteotoxic stress (the first hit) elicits adaptations or toxic
responses. If more examples of adaptations can be collected in vivo in
chronic proteotoxicity models, they would be consistent with the delayed
onset and slowly progressive nature of neurodegenerative conditions.
Conversely, toxic neuronal responses to severe proteotoxic stress may
overwhelm defenses when the stress is unyielding, as originally postulat-
ed by Selye, and are consistent with the eventual collapse of vulnerable
brain regions in Parkinson’s and Alzheimer’s disease.
REFERENCES
Adair JC, Knoefel JE, and Morgan N. 2001. Controlled trial of N-acetylcysteine for patients with prob-
able Alzheimer’s disease. Neurology 57:1515-1517
Adlard PA, Perreau VM, Pop V, and Cotman CW. 2005. Voluntary exercise decreases amyloid load in
a transgenic model of Alzheimer’s disease. The Journal of neuroscience : the official journal of
the Society for Neuroscience 25:4217-4221
Aikawa S, Matsuzawa F, Satoh Y, Kadota Y, Doi H, and Itoh K. 2006. Prediction of the mechanism of
action of omuralide (clasto-lactacystin beta-lactone) on human cathepsin A based on a struc-
tural model of the yeast proteasome beta5/PRE2-subunit/omuralide complex. Biochimica et
biophysica acta 1764:1372-1380
Alam M, and Schmidt WJ. 2002. Rotenone destroys dopaminergic neurons and induces parkinson-
ian symptoms in rats. Behav Brain Res 136:317-324
Amaral AI, Meisingset TW, Kotter MR, and Sonnewald U. 2013. Metabolic aspects of neuron-oligo-
dendrocyte-astrocyte interactions. Front Endocrinol (Lausanne) 4:54
Angot E, Steiner JA, Hansen C, Li JY, and Brundin P. 2010. Are synucleinopathies prion-like disor-
ders? Lancet neurology 9:1128-1138
Anstey KJ, Mack HA, and Cherbuin N. 2009. Alcohol consumption as a risk factor for dementia and
cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry 17:542-555
Adaptation and Sensitization to Proteotoxic Stress
45
22
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
Aridon P, Geraci F, Turturici G, D’Amelio M, Savettieri G, and Sconzo G. 2011. Protective role of heat
shock proteins in Parkinson’s disease. Neurodegener Dis 8:155-168
Asanuma M, Hirata H, and Cadet JL. 1998. Attenuation of 6-hydroxydopamine-induced dopaminer-
gic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85:907-917
Babar IA, Slack FJ, and Weidhaas JB. 2008. miRNA modulation of the cellular stress response. Future
oncology (London, England) 4:289-298
Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, and Oliveira CR.
2008. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer’s disease.
Journal of Alzheimer’s disease : JAD 15:117-128
Barkats M, Horellou P, Colin P, Millecamps S, Faucon-Biguet N, and Mallet J. 2006. 1-methyl-4-
phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn
superoxide dismutase. J Neurosci Res 83:233-242
Barkats M, Millecamps S, Bilang-Bleuel A, and Mallet J. 2002. Neuronal transfer of the human Cu/Zn
superoxide dismutase gene increases the resistance of dopaminergic neurons to 6-hydroxy-
dopamine. J Neurochem 82:101-109
Barres BA. 2008. The mystery and magic of glia: a perspective on their roles in health and disease.
Neuron 60:430-440
Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, Manning-Bog AB, Berry MJ,
White LR, and Ross GW. 2011. Glutathione Peroxidase 4 is associated with Neuromelanin in
Substantia Nigra and Dystrophic Axons in Putamen of Parkinson’s brain. Mol Neurodegener 6:8
Benarroch EE. 2005. Neuron-astrocyte interactions: partnership for normal function and disease in
the central nervous system. Mayo Clin Proc 80:1326-1338
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. 2000. Chronic
systemic pesticide exposure reproduces features of Parkinson’s disease. Nature neuroscience
3:1301-1306
Boger HA, Granholm AC, McGinty JF, and Middaugh LD. 2010. A dual-hit animal model for age-
related parkinsonism. Progress in neurobiology 90:217-229
Boll MC, Alcaraz-Zubeldia M, Montes S, and Rios C. 2008. Free copper, ferroxidase and SOD1 activ-
ities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neu-
rodegenerative diseases. Neurochem Res 33:1717-1723
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, and Rub U. 2002. Staging
of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease
(preclinical and clinical stages). J Neurol 249 Suppl 3:III/1-5
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, and Braak E. 2003. Staging of brain
pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197-211
Braak H, Del Tredici K, Schultz C, and Braak E. 2000. Vulnerability of select neuronal types to
Alzheimer’s disease. Ann N Y Acad Sci 924:53-61
Braak H, Sastre M, and Del Tredici K. 2007. Development of alpha-synuclein immunoreactive astro-
cytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s dis-
ease. Acta neuropathologica 114:231-241
Calabrese EJ. 2008a. Astrocytes: adaptive responses to low doses of neurotoxins. Critical reviews in
toxicology 38:463-471
Calabrese EJ. 2008b. Converging concepts: adaptive response, preconditioning, and the Yerkes-
Dodson Law are manifestations of hormesis. Ageing research reviews 7:8-20
Calabrese EJ. 2008c. Pharmacological enhancement of neuronal survival. Critical reviews in toxicol-
ogy 38:349-389
Calabrese EJ. 2010. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp
Toxicol 29:249-261
R. K. Leak
46
23
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, Cedergreen N, Cherian MG,
Chiueh CC, Clarkson TW, Cook RR, Diamond DM, Doolittle DJ, Dorato MA, Duke SO,
Feinendegen L, Gardner DE, Hart RW, Hastings KL, Hayes AW, Hoffmann GR, Ives JA,
Jaworowski Z, Johnson TE, Jonas WB, Kaminski NE, Keller JG, Klaunig JE, Knudsen TB,
Kozumbo WJ, Lettieri T, Liu SZ, Maisseu A, Maynard KI, Masoro EJ, McClellan RO, Mehendale
HM, Mothersill C, Newlin DB, Nigg HN, Oehme FW, Phalen RF, Philbert MA, Rattan SI, Riviere
JE, Rodricks J, Sapolsky RM, Scott BR, Seymour C, Sinclair DA, Smith-Sonneborn J, Snow ET,
Spear L, Stevenson DE, Thomas Y, Tubiana M, Williams GM, and Mattson MP. 2007. Biological
stress response terminology: Integrating the concepts of adaptive response and preconditioning
stress within a hormetic dose-response framework. Toxicology and applied pharmacology
222:122-128
Calabrese V, Cornelius C, Dinkova-Kostova AT, Iavicoli I, Di Paola R, Koverech A, Cuzzocrea S,
Rizzarelli E, and Calabrese EJ. 2012. Cellular stress responses, hormetic phytochemicals and
vitagenes in aging and longevity. Biochimica et biophysica acta 1822:753-783
Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G,
Mancuso C, Stella AM, and Butterfield DA. 2006. Nitrosative stress, cellular stress response, and
thiol homeostasis in patients with Alzheimer’s disease. Antioxidants & redox signaling 8:1975-
1986
Candilio L, Hausenloy DJ, and Yellon DM. 2011. Remote ischemic conditioning: a clinical trial’s
update. J Cardiovasc Pharmacol Ther 16:304-312
Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, and Xi G. 2005. Thrombin preconditioning
provides protection in a 6-hydroxydopamine Parkinson’s disease model. Neurosci Lett 373:189-
194
Carvey PM, Punati A, and Newman MB. 2006. Progressive dopamine neuron loss in Parkinson’s dis-
ease: the multiple hit hypothesis. Cell Transplant 15:239-250
Chacko SK, and Cheluvappa R. 2010. Increased ceruloplasmin and fibrinogen in type 2 diabetes cor-
responds to decreased anti-oxidant activity in a preliminary tertiary South Indian hospital study.
Exp Clin Endocrinol Diabetes 118:64-67
Chen H, Zhang SM, Schwarzschild MA, Hernan MA, and Ascherio A. 2005. Physical activity and the
risk of Parkinson disease. Neurology 64:664-669
Chu PW, Beart PM, and Jones NM. 2010. Preconditioning protects against oxidative injury involving
hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes.
European journal of pharmacology 633:24-32
Clark J, Clore EL, Zheng K, Adame A, Masliah E, and Simon DK. 2010. Oral N-acetyl-cysteine atten-
uates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One
5:e12333
Collins MA, Neafsey EJ, Wang K, Achille NJ, Mitchell RM, and Sivaswamy S. 2010. Moderate ethanol
preconditioning of rat brain cultures engenders neuroprotection against dementia-inducing
neuroinflammatory proteins: possible signaling mechanisms. Molecular neurobiology 41:420-
425
Cooper AJ, and Kristal BS. 1997. Multiple roles of glutathione in the central nervous system. Biol
Chem 378:793-802
Danton GH, Prado R, Watson BD, and Dietrich WD. 2002. Temporal profile of enhanced vulnera-
bility of the postthrombotic brain to secondary embolic events. Stroke; a journal of cerebral cir-
culation 33:1113-1119
Dawson VL, and Dawson TM. 2006. Mining for survival genes. Biochem Soc Trans 34:1307-1309
Del Tredici K, and Braak H. 2012. Spinal cord lesions in sporadic Parkinson’s disease. Acta neu-
ropathologica 124:643-664
Della-Morte D, Guadagni F, Palmirotta R, Ferroni P, Testa G, Cacciatore F, Abete P, Rengo F, Perez-
Pinzon MA, Sacco RL, and Rundek T. 2012. Genetics and genomics of ischemic tolerance: focus
on cardiac and cerebral ischemic preconditioning. Pharmacogenomics 13:1741-1757
Dembinski A, Warzecha Z, Ceranowicz P, Dembinski M, Cieszkowski J, Pawlik WW, Tomaszewska R,
Konturek SJ, and Konturek PC. 2006. Effect of ischemic preconditioning on pancreatic regen-
eration and pancreatic expression of vascular endothelial growth factor and platelet-derived
growth factor-A in ischemia/reperfusion-induced pancreatitis. J Physiol Pharmacol 57:39-58
DeTure M, Granger B, Grover A, Hutton M, and Yen SH. 2006. Evidence for independent mecha-
nisms and a multiple-hit model of tau assembly. Biochemical and biophysical research commu-
nications 339:858-864
Adaptation and Sensitization to Proteotoxic Stress
47
24
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, and Butterfield DA. 2010. Protein
levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive
impairment: an investigation on the role of cellular stress response in the progression of
Alzheimer disease. Brain research 1333:72-81
Di Monte DA, Lavasani M, and Manning-Bog AB. 2002. Environmental factors in Parkinson’s disease.
Neurotoxicology 23:487-502
Dickson DW. 2009. Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol
3:1-23
Dietrich WD, Danton G, Hopkins AC, and Prado R. 1999. Thromboembolic events predispose the
brain to widespread cerebral infarction after delayed transient global ischemia in rats. Stroke; a
journal of cerebral circulation 30:855-861; discussion 862
Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, and Yin XM. 2007. Linking of autophagy to
ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress
and cell viability. The American journal of pathology 171:513-524
Ding Y, and Li L. 2008. Lipopolysaccharide preconditioning induces protection against lipopolysac-
charide-induced neurotoxicity in organotypic midbrain slice culture. Neurosci Bull 24:209-218
Dirnagl U, and Meisel A. 2008. Endogenous neuroprotection: mitochondria as gateways to cerebral
preconditioning? Neuropharmacology 55:334-344
Dirnagl U, Simon RP, and Hallenbeck JM. 2003. Ischemic tolerance and endogenous neuroprotec-
tion. Trends Neurosci 26:248-254
Dringen R. 2000. Metabolism and functions of glutathione in brain. Progress in neurobiology 62:649-
671
Dringen R, Gutterer JM, and Hirrlinger J. 2000. Glutathione metabolism in brain metabolic interac-
tion between astrocytes and neurons in the defense against reactive oxygen species. European
journal of biochemistry / FEBS 267:4912-4916
Du F, Qian ZM, Zhu L, Wu XM, Yung WH, and Ke Y. 2011. A synergistic role of hyperthermic and
pharmacological preconditioning to protect astrocytes against ischemia/reperfusion injury.
Neurochemical research 36:312-318
Du F, Zhu L, Qian ZM, Wu XM, Yung WH, and Ke Y. 2010. Hyperthermic preconditioning protects
astrocytes from ischemia/reperfusion injury by up-regulation of HIF-1 alpha expression and
binding activity. Biochimica et biophysica acta 1802:1048-1053
Duan W, and Mattson MP. 1999. Dietary restriction and 2-deoxyglucose administration improve
behavioral outcome and reduce degeneration of dopaminergic neurons in models of
Parkinson’s disease. J Neurosci Res 57:195-206
Dwyer BE, Nishimura RN, and Lu SY. 1995. Differential expression of heme oxygenase-1 in cultured
cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody.
Response to oxidative stress. Brain research. Molecular brain research 30:37-47
El Ayadi A, and Zigmond MJ. 2011. Low concentrations of methamphetamine can protect dopamin-
ergic cells against a larger oxidative stress injury: mechanistic study. PLoS One 6:e24722
Erickson KI, Weinstein AM, and Lopez OL. 2012. Physical activity, brain plasticity, and Alzheimer’s
disease. Arch Med Res 43:615-621
Fairbanks SL, and Brambrink AM. 2010. Preconditioning and postconditioning for neuroprotection:
the most recent evidence. Best Pract Res Clin Anaesthesiol 24:521-534
Fan GH, Qi C, and Chen SD. 2005. Heat shock proteins reduce toxicity of 1-methyl-4-phenylpyri-
dinium ion in SK-N-SH cells. J Neurosci Res 82:551-562
Farghali H, Kutinova Canova N, and Lekic N. 2012. Resveratrol and related compounds as antioxi-
dants with an allosteric mechanism of action in epigenetic drug targets. Physiol Res
Fargnoli J, Kunisada T, Fornace AJ, Jr., Schneider EL, and Holbrook NJ. 1990. Decreased expression
of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats.
Proceedings of the National Academy of Sciences of the United States of America 87:846-850
Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, and Morley JE.
2003. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and
brain oxidative stress in aged SAMP8 mice. Journal of neurochemistry 84:1173-1183
Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW, and Petzinger GM. 2013.
Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with
early Parkinson’s disease. Neuroreport 24:509-514
Floyd RA, and Hensley K. 2002. Oxidative stress in brain aging. Implications for therapeutics of neu-
rodegenerative diseases. Neurobiol Aging 23:795-807
R. K. Leak
48
25
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
Fornai F, Lazzeri G, Bandettini Di Poggio A, Soldani P, De Blasi A, Nicoletti F, Ruggieri S, and
Paparelli A. 2006. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-pro-
teasome system in nigrostriatal toxicity. Annals of the New York Academy of Sciences 1074:84-
89
Forno LS. 1996. Neuropathology of Parkinson’s disease. Journal of neuropathology and experimen-
tal neurology 55:259-272
Fouillet A, Levet C, Virgone A, Robin M, Dourlen P, Rieusset J, Belaidi E, Ovize M, Touret M, Nataf
S, and Mollereau B. 2012. ER stress inhibits neuronal death by promoting autophagy.
Autophagy 8:915-926
Franco R, Li S, Rodriguez-Rocha H, Burns M, and Panayiotidis MI. 2010. Molecular mechanisms of
pesticide-induced neurotoxicity: Relevance to Parkinson’s disease. Chem Biol Interact 188:289-
300
Frasier CR, Moore RL, and Brown DA. 2011. Exercise-induced cardiac preconditioning: How exer-
cise protects your achy-breaky heart. J Appl Physiol
Friedman LK, and Segal M. 2010. Early exposure of cultured hippocampal neurons to excitatory
amino acids protects from later excitotoxicity. International journal of developmental neuro-
science : the official journal of the International Society for Developmental Neuroscience
28:195-205
Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, and Swaab
DF. 2007. Hypocretin (orexin) loss in Parkinson’s disease. Brain : a journal of neurology
130:1577-1585
Fu AL, Dong ZH, and Sun MJ. 2006. Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-
induced learning and memory deficits in mice. Brain research 1109:201-206
Fuller S, Steele M, and Munch G. 2010. Activated astroglia during chronic inflammation in
Alzheimer’s disease—do they neglect their neurosupportive roles? Mutat Res 690:40-49
Gai WP, Blumbergs PC, Geffen LB, and Blessing WW. 1992. Age-related loss of dorsal vagal neurons
in Parkinson’s disease. Neurology 42:2106-2111
Gao HM, and Hong JS. 2011. Gene-environment interactions: key to unraveling the mystery of
Parkinson’s disease. Progress in neurobiology 94:1-19
Gao HM, Hong JS, Zhang W, and Liu B. 2003a. Synergistic dopaminergic neurotoxicity of the pesti-
cide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s
disease. J Neurosci 23:1228-1236
Gao HM, Liu B, Zhang W, and Hong JS. 2003b. Synergistic dopaminergic neurotoxicity of MPTP and
inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. Faseb J
17:1957-1959
Gerecke KM, Jiao Y, Pani A, Pagala V, and Smeyne RJ. 2010. Exercise protects against MPTP-induced
neurotoxicity in mice. Brain research 1341:72-83
Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, and Fornai F. 2000. The role of the locus
coeruleus in the development of Parkinson’s disease. Neurosci Biobehav Rev 24:655-668
Gidday JM. 2010. Pharmacologic Preconditioning: Translating the Promise. Transl Stroke Res 1:19-
30
Giordano J, Ives JA, and Jonas WB. 2008. Hormetic responses in neural systems: consideration, con-
texts, and caveats. Critical reviews in toxicology 38:623-627
Goto Y, Niidome T, Akaike A, Kihara T, and Sugimoto H. 2006. Amyloid beta-peptide precondition-
ing reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor.
Biochemical and biophysical research communications 351:259-265
Grochot-Przeczek A, Dulak J, and Jozkowicz A. 2012. Haem oxygenase-1: non-canonical roles in phys-
iology and pathology. Clin Sci (Lond) 122:93-103
Gundersen V. 2010. Protein aggregation in Parkinson’s disease. Acta neurologica Scandinavica.
Supplementum 82-87
Guo Z, Ersoz A, Butterfield DA, and Mattson MP. 2000. Beneficial effects of dietary restriction on
cerebral cortical synaptic terminals: preservation of glucose and glutamate transport and mito-
chondrial function after exposure to amyloid beta-peptide, iron, and 3-nitropropionic acid.
Journal of neurochemistry 75:314-320
Gupte AA, Morris JK, Zhang H, Bomhoff GL, Geiger PC, and Stanford JA. 2010. Age-related changes
in HSP25 expression in basal ganglia and cortex of F344/BN rats. Neuroscience letters 472:90-
93
Adaptation and Sensitization to Proteotoxic Stress
49
26
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, and Geffen LB. 1990. Loss of brainstem sero-
tonin- and substance P-containing neurons in Parkinson’s disease. Brain Res 510:104-107
Hamidi GA, Faraji A, Zarmehri HA, and Haghdoost-Yazdi H. 2012. Prolonged hyperoxia precondi-
tioning attenuates behavioral symptoms of 6-hydroxydopamine-induced Parkinsonism. Neurol
Res 34:636-642
Hara H, Kamiya T, and Adachi T. 2011. Endoplasmic reticulum stress inducers provide protection
against 6-hydroxydopamine-induced cytotoxicity. Neurochem Int 58:35-43
Harman D. 1956. Aging: a theory based on free radical and radiation chemistry. Journal of geron-
tology 11:298-300
Harman D. 2006. Alzheimer’s disease pathogenesis: role of aging. Annals of the New York Academy
of Sciences 1067:454-460
Harman D. 2009. About “Origin and evolution of the free radical theory of aging: a brief personal
history, 1954-2009”. Biogerontology 10:783
Hineno A, Kaneko K, Yoshida K, and Ikeda S. 2011. Ceruloplasmin protects against rotenone-
induced oxidative stress and neurotoxicity. Neurochemical research 36:2127-2135
Hornykiewicz O. 1975. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser
13-21
Hornykiewicz O. 1998. Biochemical aspects of Parkinson’s disease. Neurology 51:S2-9
Hoshida S, Yamashita N, Otsu K, and Hori M. 2002. Repeated physiologic stresses provide persistent
cardioprotection against ischemia-reperfusion injury in rats. J Am Coll Cardiol 40:826-831
Intlekofer KA, and Cotman CW. 2013. Exercise counteracts declining hippocampal function in aging
and Alzheimer’s disease. Neurobiology of disease 57:47-55
Iwata A, Riley BE, Johnston JA, and Kopito RR. 2005. HDAC6 and microtubules are required for
autophagic degradation of aggregated huntingtin. J Biol Chem 280:40282-40292
Janen SB, Chaachouay H, and Richter-Landsberg C. 2010. Autophagy is activated by proteasomal
inhibition and involved in aggresome clearance in cultured astrocytes. Glia 58:1766-1774
Jellinger KA. 2009. Recent advances in our understanding of neurodegeneration. Journal of neural
transmission 116:1111-1162
Johnsen D, and Murphy SJ. 2011. Isoflurane preconditioning protects astrocytes from oxygen and
glucose deprivation independent of innate cell sex. J Neurosurg Anesthesiol 23:335-340
Johnson WM, Wilson-Delfosse AL, and Mieyal JJ. 2012. Dysregulation of glutathione homeostasis in
neurodegenerative diseases. Nutrients 4:1399-1440
Kalia SK, Kalia LV, and McLean PJ. 2010. Molecular chaperones as rational drug targets for
Parkinson’s disease therapeutics. CNS Neurol Disord Drug Targets 9:741-753
Kaneko K, Hineno A, Yoshida K, and Ikeda S. 2008. Increased vulnerability to rotenone-induced neu-
rotoxicity in ceruloplasmin-deficient mice. Neurosci Lett 446:56-58
Kaushik S, and Cuervo AM. 2009. Methods to monitor chaperone-mediated autophagy. Methods in
enzymology 452:297-324
Keller JN, Hanni KB, and Markesbery WR. 2000. Impaired proteasome function in Alzheimer’s dis-
ease. J Neurochem 75:436-439
Kiraly M, and Kiraly SJ. 2007. Traumatic brain injury and delayed sequelae: a review—traumatic brain
injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disor-
ders, including early-onset dementia. ScientificWorldJournal 7:1768-1776
Kirino T. 2002. Ischemic tolerance. J Cereb Blood Flow Metab 22:1283-1296
Kirino T, Tsujita Y, and Tamura A. 1991. Induced tolerance to ischemia in gerbil hippocampal neu-
rons. Journal of cerebral blood flow and metabolism : official journal of the International
Society of Cerebral Blood Flow and Metabolism 11:299-307
Kitagawa K. 2012. Ischemic tolerance in the brain: endogenous adaptive machinery against ischemic
stress. Journal of neuroscience research 90:1043-1054
Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura
K, Mikoshiba K, and et al. 1990. ‘Ischemic tolerance’ phenomenon found in the brain. Brain
Res 528:21-24
Koren J, 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, and Dickey CA.
2009. Chaperone signalling complexes in Alzheimer’s disease. J Cell Mol Med 13:619-630
Kultz D. 2005. Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol
67:225-257
Lanneau D, Wettstein G, Bonniaud P, and Garrido C. 2010. Heat shock proteins: cell protection
through protein triage. ScientificWorldJournal 10:1543-1552
R. K. Leak
50
27
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
Leak RK, Garbett KA, Dettmer AM, Zhang Z, Mirnics K, and Cameron JL. 2012. Physical activity is
linked to ceruloplasmin in the striatum of intact but not MPTP-treated primates. Cell and tissue
research 350:401-407
Leak RK, Liou AK, and Zigmond MJ. 2006. Effect of sublethal 6-hydroxydopamine on the response
to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J
Neurochem 99:1151-1163
Leak RK, and Zigmond MJ. 2007. Endogenous defenses that protect dopamine neurons: studies with
6-OHDA models of Parkinson’s disease. In “Parkinson’s Disease: Pathogenic and Therapeutic
Insights from Toxin and Genetic Models”. Elsevier,
Leak RK, Zigmond MJ, and Liou AK. 2008. Adaptation to chronic MG132 reduces oxidative toxicity
by a CuZnSOD-dependent mechanism. J Neurochem 106:860-874
Lee CK, Weindruch R, and Prolla TA. 2000. Gene-expression profile of the ageing brain in mice.
Nature genetics 25:294-297
Lee DH, and Goldberg AL. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends
Cell Biol 8:397-403
Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, and Lee SJ. 2010. Direct trans-
fer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucle-
inopathies. The Journal of biological chemistry 285:9262-9272
Ling Z, Chang QA, Tong CW, Leurgans SE, Lipton JW, and Carvey PM. 2004a. Rotenone potentiates
dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Experimental neu-
rology 190:373-383
Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM, and Carvey PM. 2004b. Combined toxicity of
prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat mid-
brain. Neuroscience 124:619-628
Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, and Chen RC. 1997. Environmental risk
factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48:1583-1588
Liu Y, Kato H, Nakata N, and Kogure K. 1992. Protection of rat hippocampus against ischemic neu-
ronal damage by pretreatment with sublethal ischemia. Brain research 586:121-124
Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, and Vina J. 2009. Vitamin E paradox in
Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. Journal
of Alzheimer’s disease : JAD 17:143-149
Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, DeMaggio AJ, Brickman CM, Brewer GJ,
Dick RD, Troyer MD, and Kanaley L. 1996. Increased regional brain concentrations of cerulo-
plasmin in neurodegenerative disorders. Brain research 738:265-274
Loeffler DA, Sima AA, and LeWitt PA. 2001. Ceruloplasmin immunoreactivity in neurodegenerative
disorders. Free Radic Res 35:111-118
Louro MO, Cocho JA, Mera A, and Tutor JC. 2000. Immunochemical and enzymatic study of ceru-
loplasmin in rheumatoid arthritis. J Trace Elem Med Biol 14:174-178
Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, and Yankner BA. 2004. Gene regulation and DNA dam-
age in the ageing human brain. Nature 429:883-891
Maiello M, Boeri D, Sampietro L, Pronzato MA, Odetti P, and Marinari UM. 1998. Basal synthesis of
heat shock protein 70 increases with age in rat kidneys. Gerontology 44:15-20
Manning-Bog AB, and Langston JW. 2007. Model fusion, the next phase in developing animal mod-
els for Parkinson’s disease. Neurotoxicity research 11:219-240
Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, and Di Monte DA. 2002. The herbicide
paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-
synuclein. J Biol Chem 277:1641-1644
Martin HL, and Teismann P. 2009. Glutathione—a review on its role and significance in Parkinson’s
disease. FASEB journal : official publication of the Federation of American Societies for
Experimental Biology 23:3263-3272
Martinez Banaclocha M. 2000. N-acetylcysteine elicited increase in complex I activity in synaptic mito-
chondria from aged mice: implications for treatment of Parkinson’s disease. Brain research
859:173-175
Mattson MP. 2008. Hormesis defined. Ageing research reviews 7:1-7
Mattson MP, Duan W, Wan R, and Guo Z. 2004. Prophylactic activation of neuroprotective stress
response pathways by dietary and behavioral manipulations. NeuroRx : the journal of the
American Society for Experimental NeuroTherapeutics 1:111-116
Adaptation and Sensitization to Proteotoxic Stress
51
28
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
Mattson MP, Guthrie PB, and Kater SB. 1989. Intrinsic factors in the selective vulnerability of hip-
pocampal pyramidal neurons. Progress in clinical and biological research 317:333-351
Mattson MP, and Kater SB. 1989. Development and selective neurodegeneration in cell cultures from
different hippocampal regions. Brain Res 490:110-125
Matus S, Castillo K, and Hetz C. 2012. Hormesis: protecting neurons against cellular stress in
Parkinson disease. Autophagy 8:997-1001
Mayeux R, and Stern Y. 2012. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2:
McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, and
Di Monte DA. 2002. Environmental risk factors and Parkinson’s disease: selective degeneration
of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119-127
McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, and Aizenman E. 2003.
Caspase 3 activation is essential for neuroprotection in preconditioning. Proceedings of the
National Academy of Sciences of the United States of America 100:715-720
McNaught KS. 2004. Proteolytic dysfunction in neurodegenerative disorders. International review of
neurobiology 62:95-119
McNaught KS, Belizaire R, Isacson O, Jenner P, and Olanow CW. 2003. Altered proteasomal function
in sporadic Parkinson’s disease. Exp Neurol 179:38-46
Memisogullari R, and Bakan E. 2004. Levels of ceruloplasmin, transferrin, and lipid peroxidation in
the serum of patients with Type 2 diabetes mellitus. J Diabetes Complications 18:193-197
Mezzetti A, Lapenna D, Romano F, Costantini F, Pierdomenico SD, De Cesare D, Cuccurullo F,
Riario-Sforza G, Zuliani G, and Fellin R. 1996. Systemic oxidative stress and its relationship with
age and illness. Associazione Medica “Sabin”. J Am Geriatr Soc 44:823-827
Mezzetti A, Pierdomenico SD, Costantini F, Romano F, De Cesare D, Cuccurullo F, Imbastaro T,
Riario-Sforza G, Di Giacomo F, Zuliani G, and Fellin R. 1998. Copper/zinc ratio and systemic
oxidant load: effect of aging and aging-related degenerative diseases. Free radical biology &
medicine 25:676-681
Mitchell RM, Neafsey EJ, and Collins MA. 2009. Essential involvement of the NMDA receptor in
ethanol preconditioning-dependent neuroprotection from amyloid-betain vitro. Journal of neu-
rochemistry 111:580-588
Morimoto RI. 2008. Proteotoxic stress and inducible chaperone networks in neurodegenerative dis-
ease and aging. Genes & development 22:1427-1438
Morimoto RI. 2011. The heat shock response: systems biology of proteotoxic stress in aging and dis-
ease. Cold Spring Harbor symposia on quantitative biology 76:91-99
Murry CE, Jennings RB, and Reimer KA. 1986. Preconditioning with ischemia: a delay of lethal cell
injury in ischemic myocardium. Circulation 74:1124-1136
Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM,
and Shankar SK. 2011. Evaluation of markers of oxidative stress, antioxidant function and astro-
cytic proliferation in the striatum and frontal cortex of Parkinson’s disease brains.
Neurochemical research 36:1452-1463
Nagai Y, Fujikake N, Popiel HA, and Wada K. 2010. Induction of molecular chaperones as a thera-
peutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol 11:188-197
Nichol K, Deeny SP, Seif J, Camaclang K, and Cotman CW. 2009. Exercise improves cognition and
hippocampal plasticity in APOE epsilon4 mice. Alzheimers Dement 5:287-294
Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, and Kanazawa I. 1995. Cu/Zn
superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease:
a light and electron microscopic immunocytochemical study. Acta Neuropathol 89:471-474
Nixon RA, and Yang DS. 2012. Autophagy and neuronal cell death in neurological disorders. Cold
Spring Harbor perspectives in biology 4:
Ottoboni MA. 1997. The Dose Makes the Poison. John Wiley & Sons, Inc, New York
Pan T, Kondo S, Zhu W, Xie W, Jankovic J, and Le W. 2008. Neuroprotection of rapamycin in lacta-
cystin-induced neurodegeneration via autophagy enhancement. Neurobiology of disease 32:16-
25
Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF, Jr., Spray DC,
Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, and Verkhratsky A. 2012. Glial cells in
(patho)physiology. Journal of neurochemistry 121:4-27
Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, and Wall RA. 1985. Partial protection
from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four differ-
ent antioxidants in the mouse. Neuroscience letters 60:109-114
R. K. Leak
52
29
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
Peters R, Peters J, Warner J, Beckett N, and Bulpitt C. 2008. Alcohol, dementia and cognitive decline
in the elderly: a systematic review. Age Ageing 37:505-512
Pocernich CB, and Butterfield DA. 2011. Elevation of glutathione as a therapeutic strategy in
Alzheimer disease. Biochimica et biophysica acta
Pocernich CB, La Fontaine M, and Butterfield DA. 2000. In-vivo glutathione elevation protects
against hydroxyl free radical-induced protein oxidation in rat brain. Neurochemistry interna-
tional 36:185-191
Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bjorklund A, Lindvall O, and Piccini P.
2012. Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated
with dopamine grafts. Sci Transl Med 4:128ra141
Pompella A, Visvikis A, Paolicchi A, De Tata V, and Casini AF. 2003. The changing faces of glu-
tathione, a cellular protagonist. Biochemical pharmacology 66:1499-1503
Posimo JM, Titler AM, Choi HJ, Unnithan AS, and Leak RK. 2013. Neocortex and allocortex respond
differentially to cellular stress in vitro and aging in vivo. PLoS One 8:e58596
Pothakos K, Kurz MJ, and Lau YS. 2009. Restorative effect of endurance exercise on behavioral
deficits in the chronic mouse model of Parkinson’s disease with severe neurodegeneration.
BMC Neurosci 10:6
Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts
JW, Martinez ED, Montimurro JS, Checkoway H, and Payami H. 2008. Combined effects of
smoking, coffee, and NSAIDs on Parkinson’s disease risk. Movement disorders : official journal
of the Movement Disorder Society 23:88-95
Powers SK, Talbert EE, and Adhihetty PJ. 2011. Reactive oxygen and nitrogen species as intracellular
signals in skeletal muscle. J Physiol 589:2129-2138
Prabhakar NR, and Semenza GL. 2012. Adaptive and maladaptive cardiorespiratory responses to con-
tinuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiological
reviews 92:967-1003
Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, and
Cadet JL. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resist-
ant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-
1667
Qiao M, Zhao Z, Barber PA, Foniok T, Sun S, and Tuor UI. 2009. Development of a model of recur-
rent stroke consisting of a mild transient stroke followed by a second moderate stroke in rats.
Journal of neuroscience methods 184:244-250
Quigney DJ, Gorman AM, and Samali A. 2003. Heat shock protects PC12 cells against MPP+ toxicity.
Brain Res 993:133-139
Rajapakse N, Kis B, Horiguchi T, Snipes J, and Busija D. 2003. Diazoxide pretreatment induces
delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen perox-
ide-induced toxicity. Journal of neuroscience research 73:206-214
Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P,
and Caciagli F. 1999. Trophic effects of purines in neurons and glial cells. Progress in neurobi-
ology 59:663-690
Raval AP, Lin HW, Dave KR, Defazio RA, Della Morte D, Kim EJ, and Perez-Pinzon MA. 2008.
Resveratrol and ischemic preconditioning in the brain. Curr Med Chem 15:1545-1551
Rideout HJ, Lang-Rollin IC, Savalle M, and Stefanis L. 2005. Dopaminergic neurons in rat ventral
midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate
iHSP70, following proteasomal inhibition. J Neurochem 93:1304-1313
Rideout HJ, Larsen KE, Sulzer D, and Stefanis L. 2001. Proteasomal inhibition leads to formation of
ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78:899-908
Rideout HJ, and Stefanis L. 2002. Proteasomal inhibition-induced inclusion formation and death in
cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21:223-238
Rubinsztein DC, Gestwicki JE, Murphy LO, and Klionsky DJ. 2007. Potential therapeutic applications
of autophagy. Nature reviews. Drug discovery 6:304-312
Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, and Hiltunen M. 2013.
Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1
interactome. Progress in neurobiology
Adaptation and Sensitization to Proteotoxic Stress
53
30
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K,
Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, and Shimohama S.
2004. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes
alpha-synuclein inclusions. J Biol Chem 279:10710-10719
Schipper HM. 2000. Heme oxygenase-1: role in brain aging and neurodegeneration. Experimental
gerontology 35:821-830
Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, and Arvanitakis Z. 2006.
Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment.
Neurobiology of aging 27:252-261
Schipper HM, Liberman A, and Stopa EG. 1998. Neural heme oxygenase-1 expression in idiopathic
Parkinson’s disease. Experimental neurology 150:60-68
Schultz C, Dick EJ, Cox AB, Hubbard GB, Braak E, and Braak H. 2001. Expression of stress proteins
alpha B-crystallin, ubiquitin, and hsp27 in pallido-nigral spheroids of aged rhesus monkeys.
Neurobiology of aging 22:677-682
Selye H. 1975. Stress without distress. Signet, Philadelphia
Shao Y, and McCarthy KD. 1994. Plasticity of astrocytes. Glia 11:147-155
Sharma A, Kaur P, Kumar V, and Gill KD. 2007. Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahy-
dropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol (Noisy-le-
grand) 53:48-55
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, and Marsden CD. 1994.
Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders
affecting basal ganglia. Ann Neurol 36:348-355
Silver JT, and Noble EG. 2012. Regulation of survival gene hsp70. Cell stress & chaperones 17:1-9
Sofic E, Lange KW, Jellinger K, and Riederer P. 1992. Reduced and oxidized glutathione in the sub-
stantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128-130
Son JH, Shim JH, Kim KH, Ha JY, and Han JY. 2012. Neuronal autophagy and neurodegenerative dis-
eases. Experimental & molecular medicine 44:89-98
Son TG, Camandola S, and Mattson MP. 2008. Hormetic dietary phytochemicals. Neuromolecular
Med 10:236-246
Soti C, and Csermely P. 2000. Molecular chaperones and the aging process. Biogerontology 1:225-233
Souza LC, Filho CB, Goes AT, Fabbro LD, de Gomes MG, Savegnago L, Oliveira MS, and Jesse CR.
2013. Neuroprotective Effect of Physical Exercise in a Mouse Model of Alzheimer’s Disease
Induced by beta-Amyloid1-40 Peptide. Neurotoxicity research 24:148-163
Sturtz LA, and Culotta VC. 2002. Superoxide dismutase null mutants of baker’s yeast, Saccharomyces
cerevisiae. Methods in enzymology 349:167-172
Sulzer D. 2007. Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends in
neurosciences 30:244-250
Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, and Kanthasamy AG. 2006.
Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal
models. Neurotoxicology 27:807-815
Tai KK, and Truong DD. 2010. (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol,
reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y
cells. Neuroscience letters 482:183-187
Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, Shen H, Zhao Y, Teoh ML, Yih Y, Pavanni
R, Chandran VR, and Wong MC. 2003. Dose-dependent protective effect of coffee, tea, and
smoking in Parkinson’s disease: a study in ethnic Chinese. Journal of the neurological sciences
216:163-167
Tang JX, Mardini F, Caltagarone BM, Garrity ST, Li RQ, Bianchi SL, Gomes O, Laferla FM, Eckenhoff
RG, and Eckenhoff MF. 2011. Anesthesia in presymptomatic Alzheimer’s disease: a study using
the triple-transgenic mouse model. Alzheimers Dement 7:521-531 e521
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS,
Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F,
Umbach DM, Blair A, Sandler DP, and Langston JW. 2011. Rotenone, Paraquat and Parkinson’s
Disease. Environ Health Perspect
Taysi S, Polat F, Gul M, Sari RA, and Bakan E. 2002. Lipid peroxidation, some extracellular antioxi-
dants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int
21:200-204
R. K. Leak
54
31
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
Texel SJ, Zhang J, Camandola S, Unger EL, Taub DD, Koehler RC, Harris ZL, and Mattson MP. 2011.
Ceruloplasmin deficiency reduces levels of iron and BDNF in the cortex and striatum of young
mice and increases their vulnerability to stroke. PLoS One 6:e25077
Thannickal TC, Lai YY, and Siegel JM. 2007. Hypocretin (orexin) cell loss in Parkinson’s disease.
Brain 130:1586-1595
Thompson JW, Narayanan SV, and Perez-Pinzon MA. 2012. Redox signaling pathways involved in
neuronal ischemic preconditioning. Curr Neuropharmacol 10:354-369
Titler AM, Posimo JM, and Leak RK. 2013. Astrocyte plasticity revealed by adaptations to severe pro-
teotoxic stress. Cell and tissue research
Torsdottir G, Kristinsson J, Snaedal J, Sveinbjornsdottir S, Gudmundsson G, Hreidarsson S, and
Johannesson T. 2010. Case-control studies on ceruloplasmin and superoxide dismutase (SOD1)
in neurodegenerative diseases: a short review. J Neurol Sci 299:51-54
Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, Goldstein LE, Westaway D, Huang
X, and Rogers JT. 2006. RNA therapeutics directed to the non coding regions of APP mRNA, in
vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr Alzheimer
Res 3:221-227
Unnithan AS, Choi HJ, Titler AM, Posimo JM, and Leak RK. 2012. Rescue from a two hit, high-
throughput model of neurodegeneration with N-acetyl cysteine. Neurochemistry international
61:356-368
Uryu K, Richter-Landsberg C, Welch W, Sun E, Goldbaum O, Norris EH, Pham CT, Yazawa I,
Hilburger K, Micsenyi M, Giasson BI, Bonini NM, Lee VM, and Trojanowski JQ. 2006.
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions
of alpha-synucleinopathies. The American journal of pathology 168:947-961
Uversky VN. 2009. Intrinsic disorder in proteins associated with neurodegenerative diseases.
Frontiers in bioscience : a journal and virtual library 14:5188-5238
Van Remmen H, Qi W, Sabia M, Freeman G, Estlack L, Yang H, Mao Guo Z, Huang TT, Strong R,
Lee S, Epstein CJ, and Richardson A. 2004. Multiple deficiencies in antioxidant enzymes in mice
result in a compound increase in sensitivity to oxidative stress. Free Radic Biol Med 36:1625-
1634
Verbeke P, Fonager J, Clark BF, and Rattan SI. 2001. Heat shock response and ageing: mechanisms
and applications. Cell biology international 25:845-857
Verkhratsky A, Rodriguez JJ, and Parpura V. 2012. Neurotransmitters and integration in neuronal-
astroglial networks. Neurochemical research 37:2326-2338
Vernon AC, Johansson SM, and Modo MM. 2010. Non-invasive evaluation of nigrostriatal neu-
ropathology in a proteasome inhibitor rodent model of Parkinson’s disease. BMC Neurosci 11:1
Vuckovic MG, Li Q, Fisher B, Nacca A, Leahy RM, Walsh JP, Mukherjee J, Williams C, Jakowec MW,
and Petzinger GM. 2010. Exercise elevates dopamine D2 receptor in a mouse model of
Parkinson’s disease: in vivo imaging with [(1)(8)F]fallypride. Movement disorders : official jour-
nal of the Movement Disorder Society 25:2777-2784
Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, and Takahashi H. 2000. NACP/alpha-synuclein-
positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains.
Acta neuropathologica 99:14-20
Walker LC, and LeVine H. 2000. The cerebral proteopathies: neurodegenerative disorders of protein
conformation and assembly. Molecular neurobiology 21:83-95
Walker LC, Levine H, 3rd, Mattson MP, and Jucker M. 2006. Inducible proteopathies. Trends in neu-
rosciences 29:438-443
Walters TJ, Ryan KL, and Mason PA. 2001. Regional distribution of Hsp70 in the CNS of young and
old food-restricted rats following hyperthermia. Brain research bulletin 55:367-374
Wang D, Qian L, Xiong H, Liu J, Neckameyer WS, Oldham S, Xia K, Wang J, Bodmer R, and Zhang
Z. 2006. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc
Natl Acad Sci U S A 103:13520-13525
Wei H, and Xie Z. 2009. Anesthesia, calcium homeostasis and Alzheimer’s disease. Curr Alzheimer
Res 6:30-35
Weidong L, Shen C, and Jankovic J. 2009. Etiopathogenesis of Parkinson disease: a new beginning?
Neuroscientist 15:28-35
Westergaard N, Sonnewald U, and Schousboe A. 1995. Metabolic trafficking between neurons and
astrocytes: the glutamate/glutamine cycle revisited. Dev Neurosci 17:203-211
Adaptation and Sensitization to Proteotoxic Stress
55
32
Dose-Response: An International Journal, Vol. 12 [2014], Iss. 1, Art. 3
https://scholarworks.umass.edu/dose_response/vol12/iss1/3
56
R. K. Leak
Wilson JX. 1997. Antioxidant defense of the brain: a role for astrocytes. Can J Physiol Pharmacol
75:1149-1163
Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D,
Hewett L, and Cotman CW. 2013. Walking stabilizes cognitive functioning in Alzheimer’s dis-
ease (AD) across one year. Arch Gerontol Geriatr 56:96-103
Witt SN. 2010. Hsp70 molecular chaperones and Parkinson’s disease. Biopolymers 93:218-228
Wong E, and Cuervo AM. 2010. Integration of clearance mechanisms: the proteasome and
autophagy. Cold Spring Harbor perspectives in biology 2:a006734
Wu PF, Xie N, Zhang JJ, Guan XL, Zhou J, Long LH, Li YL, Xiong QJ, Zeng JH, Wang F, and Chen
JG. 2012. Resveratrol preconditioning increases methionine sulfoxide reductases A expression
and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem
Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, and Husemann J. 2003.
Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nature medicine 9:453-457
Xie W, Li X, Li C, Zhu W, Jankovic J, and Le W. 2010. Proteasome inhibition modeling nigral neu-
ron degeneration in Parkinson’s disease. Journal of neurochemistry 115:188-199
Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, and Chen H. 2010. Physical activities
and future risk of Parkinson disease. Neurology 75:341-348
Zeevalk GD, Razmpour R, and Bernard LP. 2008. Glutathione and Parkinson’s disease: is this the ele-
phant in the room? Biomed Pharmacother 62:236-249
Zhang F, Wu Y, and Jia J. 2011. Exercise preconditioning and brain ischemic tolerance. Neuroscience
177:170-176
Zhang Y, James M, Middleton FA, and Davis RL. 2005. Transcriptional analysis of multiple brain
regions in Parkinson’s disease supports the involvement of specific protein processing, energy
metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet
B Neuropsychiatr Genet 137B:5-16
Zhang Z, Li X, Xie WJ, Tuo H, Hintermann S, Jankovic J, and Le W. 2012. Anti-parkinsonian effects
of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of
Parkinson’s disease. CNS Neurol Disord Drug Targets 11:768-773
Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, and Smith MA. 2001. Differential
activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis.
Mechanisms of ageing and development 123:39-46
Zhu X, Lee HG, Perry G, and Smith MA. 2007. Alzheimer disease, the two-hit hypothesis: an update.
Biochimica et biophysica acta 1772:494-502
Zhu X, Raina AK, Perry G, and Smith MA. 2004. Alzheimer’s disease: the two-hit hypothesis. Lancet
neurology 3:219-226
Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, and Stricker EM. 1990. Compensations after
lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci
13:290-296
Zigmond MJ, Cameron JL, Leak RK, Mirnics K, Russell VA, Smeyne RJ, and Smith AD. 2009.
Triggering endogenous neuroprotective processes through exercise in models of dopamine
deficiency. Parkinsonism & related disorders 15 Suppl 3:S42-45
33
Leak: Adaptation and Sensitization to Proteotoxic Stress
Published by ScholarWorks@UMass Amherst, 2014
